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Immune system is a highly organized network, consisting of innate and adaptive 
immune responses. The immune system has a critical role in the health of organisms and 
can be either a cure or cause of disease. In recent years, with the expanded knowledge of 
immunology that both innate and adaptive immune cells are the key mediators in cancer 
immunotherapy and tissue repair/regeneration, immunomodulatory biomaterial design 
provides a new direction for related therapeutics. Therefore, the overall goal of this 
dissertation is to design biomaterials to modulate or qualitatively shape the immune 
response, which could be ultimately used for biomedical applications of cancer 
immunotherapy and regenerative medicine. On the side of cancer immunotherapy, we first 
designed a cancer vaccine based on tumor-derived exosome, and demonstrated both 
cellular and humoral anti-tumor immunity could be induced by immunization of the 
vaccine. The designed vaccine showed a long-term protection against pre-established lethal 
challenges of B-cell lymphoma in mice. On the side of regenerative medicine, 
mesenchymal stromal cells (MSCs) are known as the sensor and switch of inflammation. 
Their widely achieved therapeutic effects for degenerative diseases are mainly contributed 
by their secretion behavior. We then designed fibrous scaffolds with the aim to potentiate 
the paracrine function of MSCs for tissue regeneration. It’s proved that MSCs showed 
enhanced secretion of anti-inflammatory and elevated capacities to induce pro-regenerative 
macrophage phenotype, when potentiated by scaffolds. The conditioned medium from 
MSCs-scaffolds are demonstrated to promote skin wound healing of mice. Based on the 
knowledge and experience from the previous two studies, we designed a MSC exosomes 
 
loaded fibrous scaffolds material to directly interact with the immune system for 
regenerative immunomodulation. The results proved our hypothesis that the scaffolds 
could recruit immune cells to the transplant site and the loaded exosomes provide them 
with regenerative immunomodulatory signals, together generating pro-regenerative innate 
and adaptive immune responses locally and systemically. This dissertation brings new 







CHAPTER 1.   INTRODUCTION 
Design of immunoactive biomaterials for therapeutic application of cancer 
immunotherapy and regenerative medicine is the overall goal of this dissertation. Before 
going through detailed motivation and objectives of this dissertation, the background 
information of basic concept of immune system, their role in treating cancer and favoring 
tissue regeneration/repair, current biomaterial strategies to interfere with the immune 
system will be introduced in the first chapter.  
1.1   Immune system 
The immune system has a critical role in the health of organisms and can be either a 
cure or cause of disease. The immune system is best known as the first line of defense 
against invading pathogens. The immune system consists of two parts: innate and adaptive 
system. The innate immune system is the first line of defense, involving 
polymorphonuclear cells (such as neutrophils, basophils and eosinophils), macrophages 
and dendritic cells (DCs). They were the first responder towards challenge 
(infection/wound) and are responsible for killing and phagocytose pathogens or debris from 
wound. The antigen presenting cells (DCs/macrophages) then carry the signals to the 
adaptive immune cells to initiate specific response against the existing challenge.  
Adaptive immunity consists of B and T lymphocytes bearing highly diverse antigen-
specific receptors that enable the immune system to recognize foreign antigen. B-cells 
mediated humoral immune response that secrete antibodies that can target pathogens for 
degradation. They could also maintain memory B cells in the bone marrow and circulating 
 
blood to protect against re-infection. T cells could be divided into T helper (Th) cells and 
cytotoxic T cells. Cytotoxic T cells can mediate direct specific killing against pathogens. 
While, T helper cells can be polarized into many subtypes, including Th1 cells, Th2 cells, 
Th17 cells, regulatory T cells (Tregs), and are capable of affecting other innate and adaptive 
immune cells by cytokine secretion. T helper 1 (Th1) cells secreting IFNγ, is associated 
with intracellular bacterial infections. Th17 cells secreting IL17, could induce secretion of 
antimicrobial peptides and defends against extracellular bacteria. Th2 cells secreting IL4, 
is related to multicellular parasites and has a role in wound healing. Finally, regulatory T 
cells (Tregs) are modulatory T cells that prevents over activation of the other immune 
polarizations and play a role in tissue regeneration. 
Though the immune system is best known as the first line of defense against invading 
pathogens, but is also essential to tissue development, homeostasis cancer immunotherapy 
and wound repair.  Actually, cells of the immune system, from innate immune system to 
adaptive immune system can sense the signals from the surrounding environment and 
together orchestrated an immunological network to create adequate response for the local 
tissue microenvironment, either to eliminate pathogen invasion, to clear the cancer cells or 
to favor tissue repair/regeneration. In the next part, the relationship between immune 
system and regeneration will be discussed. 
1.2   Immune system and regeneration 
Centuries ago, scientists were amazed by the ability of organisms such as 
salamanders to regrowth perfect copies of amputated body parts. It’s also astonishing that 
mice in embryo stage showed the ability to regenerate fully functioned heart tissue post 
 
 3 
myocardium infarction, which was lost in adult mice.[1] A widespread idea indicates that 
the change in the immune system during species revolution or individual development is 
responsible for differed outcome of regeneration. Actually, the immune system and the 
immunological environment they orchestrated is crucial to determine the quality of the 
repair response, including the behavior of stem/progenitor cells, process of angiogenesis, 
extent of scarring, and the restoration of organ structure and function by lots of studies in 
different tissue and organisms. And many key mediators in the immune system were 
identified that interfere the process of tissue repair/regeneration involving both innate 
immune cells and adaptive immune cells, which will be further introduced below. [2] 
1.2.1   Macrophage 
Macrophage is one of the most vital and well-studied mediators in immune-mediated 
regeneration because they are the first responder and final effector cells to the wound site 
as well as they have highly programming possibilities.[3] (Fig. 1.1) Once injury happens, 
the local macrophages and the recruited monocytes will massively accumulate in the 
wound sites in the following few days. After conditioning by the inflammatory stimuli 
including local growth factors and cytokines, macrophages polarize into classically 
activated (M1) or alternatively activated (M2) subtypes based on their markers, function, 
and cytokine profiles. Typically, M1 cells produce high levels of pro-inflammatory 
cytokines that aid in host defense, debris clearance and stem/progenitor cell recruitment 
and proliferation, but can also damage healthy tissue. On the contrary, M2 macrophages 
mediate wound healing, tissue repair, and the resolution of inflammation.[4] Specifically, 
the cytokine secreted by M2 macrophage, including interleukin-10 (IL-10), insulin-like 
growth factos-1 (IGF-1), vascular endothelial growth factor (VEGF), IL-4 etc., would 
 
function as mitigating the inflammation at the early stage post injury, recruiting and 
supporting the proliferation of tissue progenitor cells, inducing vascularization and 
avoiding fibrosis.[5] 
The convert of macrophage from M1 to M2 phenotype is therefore essential for 
proper wound healing and tissue regeneration. Worth mentioning, the timing of the convert 
should also be seriously considered, as shown in other study that early infiltration of M2 
macrophage to the skin wound will even hinder the process of wound closure.[6] Actually, 
M1 macrophage and their secretomes in the early time point post injury may be essential 
for progenitor cell accumulation and proliferation due to their behavior of debris clearance 
and release of inflammatory cytokines and chemo-attractive cytokines.[7] Due to the 
natural pro-inflammatory environment in the injury site driven by cell debris and danger 
signals, the presence of M1 macrophage in the wound site could naturally be achieved 
without artificial interference. Especially, the living individuals are forced to face with 
more and more severe survival environment, when evolution from water to land or 
development from fetus to adult. Therefore, the immune system is prompted to be more 
intensive in driving inflammatory immune response post injury, in order to seal the wounds 
efficiently and facilitate individual survival. In such circumstances, strategies to convert 
M1 to M2 macrophage is still one of the major strategies to generate a pro-regenerative 
immune environment. 
1.2.2   T cells 
Other than innate immune cells, adaptive immune cells are also proved to be key 
mediators in establishment of regenerative immune micro-environment in recent years. 
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Especially, T cells are proved by many studies to have a crucial role in tissue 
repair/regeneration.  
 
Figure 1.1 The highly programming possibilities of macrophages.  (Ferrante et al., 
Advanced in wound care, 2012, volume1, No.1) 
T cells have different subtypes as mentioned above and their role and underlying 
mechanisms in tissue regeneration/repair is very different and seem to vary from tissue to 
tissue. . Though some mechanisms have been revealed, the exact function of different type 
of T cells are largely unknown, which needs more investigation. The following part will 
discuss current findings of each specific T cell types and their role in tissue 
repair/regeneration. 
Regulatory T cells (Tregs)  
Tregs are considered as a pro-regenerative type of immune cells. Tregs may be 
identified by the co-expression of CD4 and CD25 and by the transcription factor FoxP3. 
to LPS challenge.10 Finally, we recently defined a
subtype of M2-like M/s induced by costimulation
of M/s with Toll-like receptor (TLR) and adenosine
A2A receptor (A2AR) agonists that display a distinct
molecular signature. A2AR stimulation by adeno-
sine in the presence of TLR agonists switches M/s
from a M1 phenotype into an angiogenic M2-like
phenotype, which we have termed ‘‘M2d.’’11 The
discovery of this and other novel M/ activation
states underscores the importance of local extra-
cellular signals in determining M/ function. Thus,
a more complete understanding of the spatiotem-
poral changes in signaling molecules during wound
healing and their effect on M/ function may allow
for the enhancement of this critical process.
EXPERIMENTAL MODEL OR MATERIAL:
ADVANTAGES AND LIMITATIONS
Studies of the influence of M/ polarization on
wound healing have traditionally utilized in vitro
culture of M/s and in vivo models of wound healing
in mice as experimental models. In vitro culture
represents a good model for the identification of M/
activation stimuli as well as elucidation of the
molecular profiles of resultant M/ populations,
because of the ability to precisely control the ex-
tracellular milieu. However, the lack of other cell
types that would normally be present, as well as
other physiological limitations, could obscure im-
portant in vivo changes that may occur in the local
environment that could affect M/ polarization.
In vivo models of wound healing certainly address
some of these concerns and the use of mice allows
for genetic manipulatio to dentify pro eins and
TARGET ARTICLES
1. Lucas T, Waisman A, Ranjan R, Roes J,
Krieg T, Muller W, Roers A, and Eming SA:
Differential roles of macrophages in diverse
phases of skin repair. J Immunol 2010; 184:
3964–3977.
2. Krausgruber T, Blazek K, Smallie T, Alza-
bin S, Lockstone H, Sahgal N, Hussell T, Feld-
mann M, and Udalova IA: IRF5 promotes
inflammatory macrophage polarization and TH1-
TH17 responses. Nat Immunol 2011; 12: 231–238.
3. Satoh T, Takeuchi O, Vandenbon A, Ya-
suda K, Tanaka Y, Kumagai Y, Miyake T,
Matsushita K, Okazaki T, Saitoh T, Honma K,
Matsuyama T, Yui K, Tsujimura T, Standley
DM, Nakanishi K, Nakai K, and Akira S: The
Jmjd3-Irf4 axis regulates M2 macrophage po-
larization and host responses against helminth
infection. Nat Immunol 2010; 11: 936–944.
Figure 1. Pathways of M/ polarization. Nonactivated M/s are polarized into distinct phenotypes by specific inducing agents and display typical changes in
gene expression. Note that not all inducing agents are included and expression profiles for different M2 M/ subtypes can differ based on the nature of
induction.
12 FERRANTE AND LEIBOVICH
 
They produce regulatory cytokines IL-10 and transforming growth factor beta (TGF-β), 
exhibiting the ability to suppress proliferation of activated T cells and modulate the activity 
of macrophages towards M2 pehnotype, thereby can indirectly influence the regenerative 
process.[8] For example, the muscle Tregs are proved to participate muscle regeneration 
through mediating myotube differentiation, M1 to M2 polarization, and attenuation of 
excessive T lymphocyte responses.[9, 10] Tregs can also secret growth factors such as 
amphiregulin, which is beneficial for progenitor cells proliferation and differentiation.[11] 
Actually, the pro-regenerative role of Tregs has been proved to be critical for the repair 
and regeneration of several tissues including skin[12], gut[13], skeletal muscle[14], and 
neuron[15]. The underlying mechanisms based on current knowledge depends on the two 
pathways mentioned above: immunomodulatory properties on other immune cells 
(especially macrophage) to form regenerative immune micro-environment and secretion of 
growth factors directly interact with progenitor cells to induce tissue regrowth. 
T helper cells and effector T cells 
T helper cells are capable of secreting a diverse range of cytokines and growth factors, 
which have beneficial or inhibitory effects on tissue healing.[16] The CD4+ T helper 1 
(Th1), secreting IFNγ and TNFα, are usually considered as T cell subsets that inhibit 
regeneration, while the The CD4+ T helper 2 (Th2), secreting IL-4 and IL-10, are 
recognized as pro-regenerative. The Th1 cells secret pro-inflammatory molecules that 
forms a positive feedback loop to increase M1 macrophage commitment and ultimately 
drive chronic inflammation that hinder regeneration. Type 2 immune polarization, which 
is important in the response to multicellular parasites and wound healing, could drive M2 
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macrophage differentiation and directly mediate progenitor cell differentiation, thus 
contributes to tissue regeneration. [17] 
 
Figure 1.2 Overview of the immune mechanisms that can impair or promote tissue 
healing or drive scarring and fibrosis. Inflammatory macrophages stimulate effector 
T cells in a positive-feedback loop. Effector T cells may also inhibit the regenerative 
capacity of tissue resident stem/progenitor cells via inflammatory cytokines. On 
contrary, a critical amount of macrophages displaying an anti-inflammatory/anti-
fibrotic phenotype contribute to regeneration through a crosstalk with Tregs, which 
in turn help sustain the anti-inflammatory/anti-fibrotic phenotype via secretion of 
anti-inflammatory cytokines such as IL-10. Tregs may also enhance the regenerative 
capacity of endogenous stem/progenitor cells through secretion of growth factors. 
Th2 cells induce/maintain anti-fibrotic/anti-inflammatory macrophages. (Z. Julier 
et al. Acta biomaterialia, 2017) 
  CD8+ (cytotoxic) T cell subsets are considered to inhibit regeneration. For example, 
fracture healing is accelerated when CD8+ T cells are depleted. On a mechanistic level, it 
has been demonstrated that Th1 cells inhibits MSC-driven bone formation in the mouse 
via IFNγ and TNFα. Similar research in humans showed that that delayed fracture healing 
significantly correlated with enhanced levels of terminally differentiated CD8+ effector 
memory T.[18] Actually, the inflammatory cytokines secreted by CD8+ T cells exhibited 
similar mechanism as Th1 immune cells 
To conclude, the whole immune system including both innate and adaptive immune 
response forms a network and together orchestrated the microenvironment for tissue 
2.1. Danger signals
Directly after tissue injury, a local inflammation is induced in
response to damage-associated molecular patterns (DAMPs, or
alarmins) and pathogen-associated molecular patterns. Endoge-
nous danger signals are typically released from necrotic or stressed
cells and damaged ECM [2,3]. Well-known DAMPs include heat
shock proteins (HSP), monosodium urate, high-mobility group
box protein 1 (HMGB1), extracellular ATP, and nucleic acids includ-
ing mitochondrial DNA. Inflammatory cytokines such as inter-
leukin (IL)-1a and IL-33 can also work as DAMPs and are
released passively from necrotic cells. In addition, fragments from
Fig. 2. The main actors of the immune response following tissue injury. (A) Kinetic of immune cell mobilization after tissue injury. Tissue resident cells including tissue-
resident macrophages and cdT cells sense tissue damage and trigger the mobilization of other immune cells. Neutrophils are followed by monocytes/macrophages and T cells.
The relative amount of each cell type recruited is not represented. (B) Overview of the initial inflammatory phase following tissue injury. Chronological events are represented
from left to right. Tissue damage is sensed by tissue-resident macrophages via DAMPs. Neutrophils are the first circulating immune cells recruited to the site of injury,
promoting inflammation and monocyte/macrophage recruitment. The inflammation is initially maintained by pro-inflammatory M(IFN-c) macrophages, before being
eventually resolved with the help of M(IL-4) macrophages. (C) Overview of the immune mechanisms that can impair tissue healing or drive to scarring and fibrosis. M(IFN-c)
macrophages stimulate effector T cells in a positive-feedback loop. Effector T cells may also inhibit the regenerative capacity of tissue resident stem/progenitor c lls via
inflammatory cytokines. M(IL-4)-like macrophages with a pro-fibrotic activity encourage ECM protein deposition and subsequent fibrosis (scarring), preventing full
regeneration of the original tissue. Pericytes increase immune cell mobilization and differentiate into scar forming myofibroblasts via growth factors such as TGF-b1. (D)
Overview of the pro-regenerative immune mechanisms. A critical amount of macrophages displaying an anti-inflammatory/anti-fibrotic phenotype (e.g. M(IL-10)-like)
contribute to regeneration through a crosstalk with Tregs, which in turn help sustain the anti-inflammatory/anti-fibrotic phenotype via secretion of anti-inflammatory
cytokines such as IL-10. Tregs may also enhance the regenerative capacity of endogenous stem/progenitor cells through secretion of growth factors. Th2 cells induce/maintain
anti-fibrotic/anti-inflammatory macrophages. Black arrows indicate a differentiation path or secretion of immune modulators/morphogens. Black dashed arrows indicate a
hypothetical differentiation path. Red arrows indicate induction. Blue arrows indicate inhibition.
Z. Julier et al. / Acta Biomaterialia xxx (2017) xxx–xxx 3
Please cite this article in press as: Z. Julier et al., Promoting tissue regeneration by modulating the immune system, Acta Biomater. (2017), http://dx.doi.
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regeneration. (Fig. 1.2) Though many mechanisms of immune-mediated regeneration 
remains to be elucidated, the close relationship between immune cells and tissue 
regeneration has been largely proved. Therefore, modulating the polarization of the 
immune response becomes a promising strategy to induce tissue regeneration. 
1.3   Immunomodulatory properties of MSCs 
Mesenchymal stromal cells (MSCs) are widely used in clinical treatment for degenerative 
diseases. Their secretomes consist of bioactive components with the function of 
immunomodulation, pro-angiogenesis, anti-apoptosis etc. Especially, MSCs could sense 
the immune environment and modulate broad spectrum of immune cells by secreting 
immunomodulatory secretomes, that modulate the immune system towards regenerative 
phenotype. Therefore, the immunomodulatory secrete behavior makes MSCs, especially 
their secretion product, a potential candidate in immune-mediated regeneration. 
1.3.1   MSCs secretome in regenerative medicine 
Mesenchymal stromal cells (MSCs) are multipotent adult stem cells capable of 
differentiating into multiple lineages, including osteoblasts, adipocytes, chondrocytes and 
myoblasts, under different stimuli and culture conditions. In recent decades, MSCs are one 
of the most widely investigated cell types in regenerative medicine and have achieved 
promising therapeutic results in treating graft-versus-host disease, myocardial infarction, 
cerebral stroke and wound healing etc.[19, 20] However, studies have shown that the multi-
lineage potential of MSCs may contribute little to their therapeutic effects. Instead, the 
paracrine products and extracellular vesicles (EVs) of MSCs, exhibiting multifaceted 
functions including immunomodulation, angiogenesis, anti-apoptosis, anti-scarring, 
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chemoatrraction and modulating local stem and progenitor cells are the main contributor 
to tissue repair/regeneration.[21] 
1.3.2   Immunomodulatory paracrine function of MSCs 
One of the most important function of MSC secretome is their immunomodulatory 
properties. In particular, the anti-inflammatory molecules  secreted by MSCs under certain 
priming conditions, such as by being exposed to pro-inflammatory molecules (e.g. TNF-α 
and IFN-γ) would modulate both innate and adaptive immune response towards pro-
regenerative directions.[22] To be specific, MSCs secrete indoleamine-2, 3- dioxygenase 
(IDO), prostaglandin E2 (PGE2) and tumor necrosis factor α (TNF-α)-stimulated gene 6 
(TSG-6), TGF-β, IL10, IL-6 etc.,  that are able to modulate macrophage towards M2 
phenotype, inhibit dendritic cell (DC) maturation, increase regulatory T cell population, 
induce Th2 immune response, suppress differentiation of B cells and T cells and suppress 
NK cell activity. These modulatory effects are highly consistent with the immune 
environment needed for a benign regenerative outcome mentioned above, therefore making 
MSCs secretome  potential candidates in immune-mediated tissue repair/regeneration  [23] 
Worth mentioning, the anti-inflammatory properties of MSCs also achieved by cell-
cell contact. The PD-L1 and PD-L2 expressed on the MSCs cell membrane wound interact 
with the PD-1/PD-2 molecules on the immune cell membranes and hinder their 
inflammatory behavior. Studies have shown that trans-well culture of MSCs and immune 
cells will diminish the MSCs immunomodulatory properties compared to co-culture system 
due to the avoidance of cell-cell contact.  
1.3.3   Immunomodulatory properties of MSC EVs 
 
EVs are small phospholipid vesicles released from a wide variety of cell types 
including MSCs, aiming at cell-cell and cell-environment communication. Based on the 
size and intracellular origin, they can be divided into: exosomes, microvesicles (MVs) and 
apoptotic bodies. EVs with a diameter ranging from 30 to 100 nm are exosomes with the 
surface marker of CD9, CD63 and CD81. They are formed inside multivesicular bodies 
that fuse with the plasma membrane resulting in their release into the extracellular space.  
EVs with diameter ranging from 100–1000 nm are categorized as MVs, which are formed 
by budding from the plasma membrane in response to a wide variety of stimuli. The largest 
EVs, which range from 1 to 5 µm in diameter are the apoptotic bodies. And from here on, 
this dissertation will focus on MVs and exosomes, which will be collectively referred to as 
EVs.  
MSC-EVs assemble similar properties of MSCs due to their retaining surface 
proteins, enzymes, RNA and miRNA from their cell of origin. Moreover, EVs have been 
shown to have equivalent therapeutic effects in many disease, including cardiovascular 
disease, neurological disorder, kidney damage, wound healing and immunological 
disease.[24-26] The immunomodulatory factors, such as Gal-1, PD-L1, TGF-β, IL10, 
miRNAs either anchored on the phospholipid bi-layer or trapped inside the EVs as cargoes 
endowed EVs the ability to modulate the immune system with equivalent capacity as their 
origin cells. Similar to the MSCs, EVs could modulate macrophage towards M2 phenotype, 
increase regulatory T cell population and induce Th2 immune response, inhibit T cell 
proliferation as reported in other studies.  
Taken together, MSC paracrine factors and secreted EVs contains a cohort of 
immunomodulatory components that could targeting broad types of immune cells. During 
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tissue injury, MSCs could shape the immune response to favor the regenerative process 
through their secretome. This makes MSCs secretomes a promising candidate in the 
development of immunomodulatory regenerative medicine as a substitute of cells. 
1.4   Biomaterial-based strategies for immunomodulation in regenerative medicine 
The immune response towards biomaterials are inevitable and thus can be used to 
modulate the immune system to favor regeneration. Many aspects of biomaterials are 
editable to generate desired immune response, including their chemical/physical/biological 
properties. Therefore, biomaterial design provides a multi-functional tool-box for us to 
modulate the immune system towards regeneration. 
One strategy of biomaterials design is to avoid or minimize the interaction with the 
immune system. Therefore, the biomaterials were designed to be inert to minimize the 
possible foreign body reaction without adding inflammatory burden to tissue regeneration. 
Later on, the biomaterials were designed to actively absorb danger signals or chemokines 
from the injured sites to mitigate the inflammation caused by tissue damage in the early 
phase. With the discovery of immune system’s multiple impact on regenerative process, 
the immunomodulatory properties of regenerative biomaterials should be added to the 
criteria of the material design. Many biomaterials were then designed as carriers for the 
delivery of immunomodulatory molecules, genes or cells. However, these strategies 
seemed to have limited outcome for promoting tissue regeneration as single cytokine or 
gene delivery may have limited potency to impact the overall immune system. Moreover, 
the aboving material design are mostly designed to target macrophage and manipulate their 
phenotype. To better interfere with the immune system in terms how, where and when to 
 
be activated is crucial for the building of a pro-regenerative immune environment. 
Therefore, introducing immunoactive components to material design to directly modulate 
and qualitatively shape multiple arms of the immune system, not only macrophage but also 
adaptive T cells, is a new direction for biomaterial design in regeneration medicine in the 
future. By optimizing the surface chemical/physical and topological properties of materials, 
or utilizing the inherent ability of nature-derived biomaterials to cross talk with immune 
system, materials could be designed to be immunoactive and achieve more potent and 
broader impact on immune system to favor tissue repair/regeneration. 
1.4.1   Biomaterials design to mitigate inflammatory immune response 
Inert biomaterials to avoid immune response  
In the early time, biomaterials are designed to be inert and invisible to avoid the 
interaction with the immune system. Based on the knowledge back then, the biomaterials 
that cause immune response, were recognized as foreign body response, is detrimental to 
tissue regeneration. Therefore, the materials should be designed to be inert in order to 
reduce immune cell recruitment. Synthetic materials, such as poly(lactide coglycolide) 
(PLG), poly(ethylene glycol) (PEG) , and poly(vinyl alcohol) (PVA) have relatively low 
protein absorption level and can be modified to the biomaterials in order to mitigate the 
immune response.[27] 
Biomaterials for pro-inflammatory signal scavenging  
Another biomaterial-based strategy to mitigate the immune response in the injured 
sites is to design scavenging materials to remove pro-inflammatory signals in the body. 
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The injured sites will produce pro-inflammatory signals post injury, prepared to fight 
against possible pathogen invasion. These signals could lead to acute inflammation and 
harm the local tissue. They could also result in long-term chronic inflammation that 
hindered the healing process. In recent years, biomaterials are therefore designed to 
scavenge these pro-inflammatory signals and thus dampen the inflammation post injury 
and promote wound healing. 
These pro-inflammatory signals include damage associated molecular patterns 
(DAMPs), pathogen associated molecular patterns (PAMPs) and inflammatory 
chemokines etc. The DAMPs and PAMPs could trigger strong intercellular signal cascades 
through binding to pattern recognition receptors (PRRs) or (toll-like receptors) TLRs of 
the immune cells and result in strong inflammatory response that may hinder the 
regeneration. Pathogenic nucleic acids (e.g., viral RNAs, bacterial DNAs) as well as 
nucleic acids released by necrotic cells are origin of DAMPs and PRRs. Therefore, 
materials were designed to have the ability to immobilize the nucleic acid and resolve the 
inflammation. For example, some nucleic acid-binding polymers such as PAMAM could 
be immobilized to scaffolds or particles for nucleic acid scavenging in the injury sites.[28-
30] 
Chemokines are class of signaling molecules that could selectively recruit and 
activate cells during inflammation. During the wound healing process, chemokines are 
released by tissue-specific cells and resident immune cells at the site of injury to establish 
a chemo-attractive gradient that promote the invasion of blood-derived immune cells, 
which are essential for the initial inflammatory phase of acute wound healing. In chronic 
inflammation also related to high concentration of chemokines released to the injury sites. 
 
Because the chemokines could bind to extracellular matrix glycosaminoglycans (GAGs), 
material based on GAGs were designed to remove the chemokines from the wound site 
and resolve the inflammation. 
1.4.2   Biomaterials as delivery tool for immunomodulation. 
To modulate the immune system towards regeneration, components with 
immunomodulatory properties could be administrated to the injured sites, such as anti-
inflammatory cytokines and cytokines, miRNA, immune cell chemokines, and even 
primed immune cells. Therefore, the biomaterials could be used as a delivery tool to 
efficiently delivery theses immunomodulatory components to the target tissue.[31] 
Deliver cytokines 
Based on the delivery cargoes and the target cells, the biomaterials could be special 
design to meet the delivery criteria.[32] For example, soluble anti-inflammatory proteins 
such as IL4 and IL10, typically have an inherently short half-life when administrated in 
vivo. Encapsulate these cytokines with hydrogels could be more appropriate for the 
resolution of acute inflammation.[33, 34] On contrast, when dealing with chronic 
inflammation, it may be better to encapsulate the cytokines in synthetic polymer materials 
or immobilization to the scaffold surface for sustained release and prolonged bioactivity in 
vivo.[35] 
Deliver nucleic acids 
Biomaterials could also be designed to deliver DNA or RNA through packaging with 
proteins, polymers or lipids to create particles to overcome the extracellular and 
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intracellular barriers to efficiently delivery the gene to the target cells. The delivery of a 
gene can be employed to increase the expression of a target gene and the delivery of siRNA 
or miRNA could specifically decrease the expression of certain gene. Both strategies are 
potentially useful in increasing or decreasing the expression of immune-related factors. For 
example, delivery of miR-146a using PEI nanoparticles was able to inhibit renal fibrosis 
through suppression of the infiltration of macrophages.[36] 
Deliver cells 
Deliver cells by materials, especially those have been identified as key mediators in 
the immune-mediated regeneration, is another direct strategy for regenerative immune 
modulation. As have mentioned, the MSCs are sensors of inflammation and could switch 
pro-inflammatory environment to anti-inflammatory environment by secreting 
immunomodulatory molecules, therefore can be delivered by scaffolds to mitigate 
inflammation conditions.[37] Proper delivery of M2 macrophage and Tregs to the 
inflammation sites could help resolving the inflammation.[38] In some circumstance, 
delivery of M1 macrophage could also be pro-regenerative as pro-inflammatory cytokines 
are related to debris clearance and progenitor cell proliferation. However, it has to be kept 
in mind that the timing and the specificity of injured tissue needs to be seriously considered 
when delivering certain immune modulators. As the immune signals and network are time 
and tissue, even species specific, and inappropriate delivery may be detrimental and induce 
opposite effects. 
1.4.3   Immunoactive biomaterial design 
 
Immunoactive biomaterials could have direct interaction with the immune systems 
and broadly activate the regenerative immune response. Synthetic materials with optimized 
chemical/physical/topological properties are mainly designed to modulate macrophage 
behavior to favor regeneration. The most recent explored nature-derived extracellular 
matrix are more potent to interact with the immune system by generating new adaptive 
immune response other than innate immune response. 
Chemical and physical properties 
The types and the pattern of surface chemistry of biomaterials could drive different 
immune responses. For example, tuning the surface amine or acrylic acid group and their 
density on the surface significantly modulated the osteoimmune environment, such as the 
expression of inflammatory cytokines.[39] The hydrophilicity, and surface charge could 
interfere with material-immune cell interaction, with the observation that hydrophilic and 
anionic surfaces promote an anti-inflammatory type of response by dictating selective 
cytokine production by biomaterial adherent monocytes and macrophages, whereas the 
hydrophobic surfaces increased monocytes and macrophages adhesion density and foreign 
body giant cell (FBGC) formation.[40] FBGC formation can also be limited by the size of 
the biomaterials.[41, 42] Spheres with increasing diameter (1.5– 2.5 mm) reduce the 
foreign body response compared to smaller diameter (<1 mm), and electrospun fibers (EF) 
with diameter of 5 µm could induce M2-macorphage commitment and tissue resident stem 




Topographic property is another aspect worth considering when design 
immunoactive biomaterials. Porous materials promote vascularization and less fibrous 
tissue encapsulation relative to non-porous biomaterials.[43] Porosity on the scale of 30–
40 µm also increased the ratio of anti-inflammatory M2 to pro-inflammatory M1 
macrophages, leading to fewer FBGC and enhanced tissue repair.[41] Similarly, aligned 
electrospun nanofibers minimize the host immune reaction, enhance tissue-scaffold 
integration, and generate a thinner fibrous capsule compared to random fibers and films.[44] 
Materials with varied micro-groove pattern could also modulate macrophage phenotype. 
Extracellular matrix (ECM) materials 
By separating of cells from excised tissues, the decellularized ECM scaffolds could 
be harvested from many tissues. ECM scaffolds have bio-functional components and 
unique structures that are used to create a pro-generative environment. Worth mentioning, 
the ECM scaffolds showed potent immunomodulatory properties in vivo. ECM has shown 
to modulate the wound immune microenvironment through macrophage polarization. They 
could manipulate the macrophage phenotype towards M2 phenotype. Although the 
underlying mechanism is still not fully elucidated, studies have shown the matrix-bound 
micro-vesicles embedded in the ECM and the digested peptide fragments showed strong 
immunomodulatory function, which could be the reason for immunomodulatory properties 
of ECM materials. Other than regulate macrophage phenotype, ECM scaffolds were also 
proved to induce Th2 immune response that is dispensable for their regenerative role in 
large volume muscle disease.[45, 46] Therefore, The ECM material is a natural scaffold 
that could modulate both innate immune response and adaptive immune response to favor 
the process of tissue repair/regeneration.  
 
In short summary, the immune system could be manipulated by varied biomaterial-
based strategies to favor tissue repair/regeneration. Most studies focus on minimizing 
inflammation or manipulating macrophage phenotype post injury and success has been 
achieved in many tissues. With the accumulated knowledge that the immune system 
participates in many stages of tissue repair/regeneration more broadly than we imagine, the 
immunoactive biomaterials with the criteria to generate new immune events to interact with 
both innate and adaptive immune system is promising future direction. The immunoactive 
biomaterials design is at least as potent as stem cell based biomaterial design in 
biomaterials-based regenerative medicine. 
1.5   Biomaterial-based strategies for cancer immunotherapy 
To fully eradicate cancer utilizing immune system is a promising therapeutic 
strategies to cure cancer. Cancer vaccine is one of the most efficient strategies of cancer 
immunotherapy aims to adequately active innate and adaptive immune system to 
specifically kill cancer cells. The biomaterials in cancer vaccine are designed to facilitate 
the immune system activation meanwhile providing tumor-specific antigens to the antigen 
presenting cells. 
1.5.1   Concept of cancer vaccine 
Cancer immunotherapy aims to generate specific anti-tumor immunity that could 
suppress or eradicate the tumor without harming the healthy cells. Three key factors need 
to be considered during cancer vaccine design: a) the antigen source that provide specificity 
against tumor for immune system; b) the adjuvants that assist immune system activation; 
c) a delivery method to efficiently deliver the antigen and adjuvants to the immune 
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system.[47] Source of antigens could be originating from identification of certain idiotype, 
irradiated tumor cells, tumor cell lysate, tumor-derived exosomes. To identify certain 
idiotype for each cancer and patient could be time and money consuming. The other antigen 
source however provides the whole range and personalized tumor antigens, might more 
practical for providing antigen source. The adjuvant includes bacterial derived nucleic 
acid/lipids, chemical substance, heat-shock protein etc. One of the most common used 
adjuvants wound toll-like receptor (TLR) ligands, which could bind to the TLR on the 
immune cells and non-specifically activate the immune system.[48] To achieve better 
delivery efficiency of antigen and adjuvants to the immune cells, biomaterials could be 
used in many ways, which will be discussed later.  
To achieve the goal of cancer eradication, a systemic adaptive T and B cell-mediated 
anti-cancer immunity need to be driven. The immature DCs migrates to the location of 
antigen/adjuvants, uptake the antigens and sense the adjuvants via TLR, finally become 
matured with the expression of surface co-stimulatory molecules. Once the DCs were 
matured they have the ability to present the antigens to the T cells either at the site of 
vaccination if the ongoing reaction attracts T cells, or in the draining lymph node where 
the antigen presented by dendritic cells activates Th cells. The activated Th cells will 
release IFNγ and contribute to both cell-mediated lysis through cytotoxic T lymphocytes 
(CTL) activation and the differentiation of B cells into plasma cells, which produce anti-
tumor antibodies. The CTL will then migrate from the lymph node and infiltrate to the 
cancer lesion, recruit and activate innate immune cells to secrete more TNFα and IFNγ that 
lead to inhibited tumor invasion. CTL will also release Granzyme B to direct lysis the 
tumor cells. When the antigen is expressed on the cell membrane, antibodies secreted by 
 
plasma cells might activate complement-mediated lysis, or antibody-dependent cellular 
cytotoxicity, cause killing of tumor cells. The long-term maintenance of a protective 
immune response guarantees surveillance and the continuing elimination of tumor cells as 
soon as they emerge to prevent tumor recurrence. 
1.5.2   Materials in cancer vaccine 
Biomaterials based cancer vaccine has longer research history than 
immunomodulatory biomaterial for regeneration. To eradicate cancer utilizing immune 
system, emphasis is placed on dendritic cell maturation to present antigen to the adaptive 
immune system in the lymph nodes. Therefore, biomaterials were designed to facilitate the 
antigen presentation to innate immune system as well as efficiently generate anti-cancer 
adaptive immunity.[49-51] 
Particulate delivery system 
As mentioned earlier, to design a therapeutic cancer vaccine, how to deliver the 
antigens and adjuvants to the immune cells efficiently is a great challenge. Micro- and-
nano-particles made of polymers, liposomes or natural derived vesicles are promising tool 
for antigen and adjuvant delivery to induce potent cellular and humoral immunity.[52] The 
encapsulate or surface coating antigens and adjuvants to the particles could increase the 
availability of the antigens and adjuvants, as direct injected of antigens and adjuvants will 
diffuse very quickly in the body and achieve limited immunogenicity.[51] Moreover, 
loading both antigens and adjuvants to one particle also enable one APC to uptake the two 
key components at the same time, which has been proved to enhance the magnitude of 
immune activation.[53, 54] Similarly, it has been proved that using of multiple adjuvants 
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at the same time may cause synergistic effect to activate immune system compared to one 
alone, thus particles loading multiple adjuvants allow the co-delivery of adjuvants to one 
APC.[55] 
Scaffolds for building “immune-active center” 
The materials design focused on the passive delivery of antigens and adjuvants to the 
immune cells. However, materials could be designed to create an in situ “immune priming 
center” and thus to promote the attraction of antigen presenting cells (APCs), APC 
differentiation and activation, and loading with antigen to promote the immune response. 
Many material design have successfully achieved better vaccine efficacy based on this 
strategy. [49] 
Hydrogels are three-dimensional, hydrated networks of crosslinked polymers. 
Injectable hydrogels could realize the sustained release of antigens and adjuvants to the 
surrounding environment.[56] Moreover, they could recruit DCs to the injection site and 
deliver the antigens and adjuvants to the DCs. Similar strategy has been realized by design 
of injectable spontaneously assembling scaffolds consisting of mesoporous silica rods 
(MSRs). When loaded with OVA, GM-CSF and CpG-oligonucleotides, this scaffold-based 
vaccine elicited potent immune serum antibody responses and cytotoxic T cell responses 
that enhanced protection against OVA-expressing tumors.[57] 
1.6   Motivation and research objectives 
1.6.1   Motivation 
 
The immune system is a highly organized network that have a central role to 
modulate many critical biological events. The most well-known function of immune 
system is as the first line to provide protection against pathogen invasion. It is also 
commonly known that the abnormality of the immune system will lead to allergies and 
autoimmune diseases. However, in recent decades, the biologists have broadened our 
knowledge about the role of immune system, especially in the cancer immunotherapy and 
regenerative immunomodulation field. 
The concept of cancer immunotherapy is to generative specific anti-tumor immunity 
that could suppress or eradicate the tumor without harming the healthy cells. With 
Sipuleucel-T becomes the first cancer vaccine proved by US Food and Drug 
Administration (FDA), the cancer vaccine showed promising clinical application potential 
and may eventually become the cure for cancer. However, it is much more difficult to 
develop a cancer vaccine with therapeutic efficacy, compared to pathogen vaccine, due to 
the complicated immunosuppressive environment brought by cancer. Three challenges 
need to be overcome for a successful cancer vaccine development: the identification of 
tumor specific antigen, the immune stimulator that facilitate the activation of the immune 
system and the efficient delivery tool to deliver the antigen and the immune stimulator to 
the immune cells. Biomaterials based strategies is a powerful tool box that could provide 
possible solutions to these challenge. Therefore, how to design materials to provide 
solutions to these challenge and enhance the therapeutic efficacy of cancer vaccine is worth 
exploring. 
With the identification of M2 macrophage one decade ago, the role of macrophage 
and their versatile of phenotypes in tissue regeneration has been largely studied and since 
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then the immune system is closely connected with regeneration. In recent year, the adaptive 
immune cells, especially T helper 2 cells and Tregs were identified as pro-regenerative in 
many tissues such as muscle, heart, skin and neuron. As of today, with new findings that 
keep involving other types of immune cells to the regenerative process such as innate 
lymphoid cells (ILC)[58] and gamma delta T cells[59] etc., the immune-mediated 
regeneration is a brand new and promising direction to head for in the future regenerative 
medicine realm. Actually, very limited achievements were made from traditional tissue 
engineering strategies, which emphasis the utilize of stem cells, scaffolds and growth 
factors to replace the injured tissue. The broadened knowledge of immune-mediated 
regeneration provide us an alternative and may be effective strategy to modulate the 
immune system by materials and induce endogenous regenerative process. Therefore, to 
achieve the goal of designing a biomaterial that have the ability to intentionally manipulate 
the immune cell behavior and generate a pro-regenerative immune environment in vivo is 
highly motivated. 
1.6.2   Research objectives 
The overall objectives for this dissertation is to design biomaterials to qualitatively 
shape the immune response for biomedical application of cancer immunotherapy and 
regenerative medicine. 
A competent cancer vaccine should provide solutions for the three challenges 
mentioned before: the identification of tumor specific antigen, the immune stimulator that 
active the immune system and the efficient delivery tool to deliver the antigen and the 
immune stimulator to the immune cells. The biomaterials could be designed as delivery 
 
tool that allow co-delivery of antigens and immune stimulators. Bioaterials could also be 
designed to form an active center that attracts immune cells to the injection sites and 
activate them. Though many promising results have been achieved to increase anti-cancer 
immunity by involving biomaterials in cancer vaccine design, to design a material that 
solve the three challenge simultaneously is still challengeable. Tumor derived exosomes 
are nano-vesicles secreted by tumor cells with endogenous antigens and immune 
stimulators. As exosomes are vesicles that aims to transfer the cargoes for cell-cell and 
cell-environment communications, they are natural nano-particles for delivery. Therefore, 
in the chapter 2 of this dissertation, the tumor derived exosomes based cancer vaccine were 
designed to solve these challenges. The mechanistic immune response driven by tumor-
derived exosomes were carefully studied in vivo and the therapeutic efficacy to fight 
against the B lymphoma were evaluated. 
The exosomes secreted by cancer cells hold the potential to activate the immune 
system to fight against cancer. On the other side, the secretome of mesenchymal stromal 
cells (MSCs) showed strong immunomodulatory properties that could favor tissue 
repair/regeneration. In fact, MSCs are one of the most widely used stem cells in tissue 
regeneration. Their therapeutic role is proved to be contributed by the secretome with the 
function of immunomodulation, pro-angiogenesis, anti-scar, chemo-attraction for 
progenitor cells etc. Therefore, manipulating the secretome of MSCs by materials, 
especially the immunomodulatory and pro-angiogenic properties, is a promising strategy 
for MSC based regenerative medicine design. Moreover, the scaffolds were usually used 
as a delivery tool for MSCs in regenerative medicine, however, their intrinsic interaction 
with MSC in terms of paracrine function is very much neglected. In chapter 3 of this 
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dissertation, a fibrous scaffold with varied topological properties was investigated for the 
objective of enhancing MSCs paracrine function. The immunomodulatory and pro-
angiogenic secretion were studied in the scaffolds-MSCs interaction system. The ability to 
modulate the macrophage phenotype in vitro and in wound healing model in vivo and the 
final therapeutic effects by scaffold-MSC secretome were studied. 
Immunomodulatory material design for cancer vaccine have a longer history and 
have achieved many successful examples, compared to regeneration field. Even though the 
overall direction of immunomodulation of cancer vaccine and regeneration is different, the 
biomaterial based strategies for immunomodulation could be borrowed from cancer 
vaccine for regenerative immunomodulatory material design. One of the successful 
strategy in cancer vaccine design is to utilize the immune response towards materials to 
attract immune cells to the place of materials and send the anti-cancer signals carried by 
the materials to the recruited immune cells. Inspired by this strategy, meanwhile on the 
basis of the previous two objectives, in the chapter 4 of this dissertation, a MSC exosomes-
loaded scaffolds were designed for direct regenerative immunomodulation in vivo. The 
ability of immune cell recruitment and their regenerative behavior change by the exosome-
scaffold materials were carefully studied. Even though the adaptive immune cells are 
identified as key mediator in regeneration, many regenerative immunomodulatory design 
focused on the immune response of innate immune cells especially macrophage. Therefore, 
the adaptive immune response driven by exosome-scaffold in the reomote lymphatic 




1.7   Specific aims 
Specific aim 1: Development of cancer vaccine based on tumor-derived exosomes to 
generate anti-cancer immunity against B lymphoma 
We hypothesized that tumor derived exosomes harboring the endogenous tumor 
antigens and immune stimulating molecules, meanwhile structured as a natural nano-
particle aiming for delivery, could be used in cancer vaccine development against B 
lymphoma. Furthermore, co-administration of the tumor-derived exosomes with toll like 
receptor agonists could further enhance the dendritic maturation and antigen presentation 
efficiency, thus generating a stronger anti-tumor immunity. The potential cellular and 
humoral immune responses and long term survival efficacy that could be driven by 
immunization of tumor-derived exosomes were studied in a one week pre-established 
metastatic lethal B lymphoma model. 
Specific aim 2: Investigate the function of fibrous scaffolds to potentiate the 
immunomodulatory paracrine action of mesenchymal stromal cells (MSCs) 
We hypothesized that the fibrous scaffolds and the varied topological cues could 
potentiate the immunomodulatory and angiogenic paracrine function of MSCs and promote 
wound healing in vivo. Fibrous scaffolds with different topological cues were fabricated 
by electrospinning technique. The effects of the fibers on MSCs to produce pro-angiogenic 
and anti-inflammatory paracrine factors were investigated. The function of these paracrine 
factors were further studied through collecting conditioned-medium from different culture 
systems and applying it to cultures of endothelial cells and macrophages in vitro and a skin 
wound-healing model in vivo. 
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Specific aim 3: Design of immunoactive exosome-loaded scaffolds with the immune 
cell recruitment and education properties for regeneration 
We hypothesized that the MSC exosome loaded scaffolds would drive regenerative 
immunomodulation in the wound healing model. The possible mechanism could be: the 
fibrous scaffolds would recruit immune cells to the transplant site due to foreign body 
reaction in vivo; the recruited immune cells will then receive the immunomodulatory 
signals from the MSC exosomes and generate immune environment that favor the tissue 
repair/regeneration. Through series of chemical modification, electrospun fibrous scaffolds 
were covalently conjugated with polyethylenimine (PEI) to passively load exosomes 
through static interaction. The exosome loaded scaffolds were then applied to a wound 
healing model in vivo and the immunomodulatory properties of the innate and adaptive 
immune response were evaluated in both local sites and remote lymphatic organs. 
  
 
CHAPTER 2.   DEVELOPMENT OF CANCER VACCINE BASED 
ON TUMOR-DERIVED EXOSOMES FOR B LYMPHOMA 
IMMUNOTHERAPY 
Tumor derived exosomes (Texo) are potential antigen source for cancer 
immunotherapy to solve the challenge of identifying particular tumor antigen. However, 
the therapeutic role of Texo in established diffuse large B cell lymphoma (DLBCL) model 
and the fundamental immune response driven by Texo in vivo remains elusive. In this study, 
we developed a Texo-based therapeutic vaccine that could generate long-term protection 
against aggressive metastatic B lymphoma. The anti-tumor immunity driven by 
immunization of Texo was carefully studied. The result showed Texo vaccine enhanced 
both Th1 and Th2 immune response in spleen, meanwhile induced germinal center 
formation in the draining lymph nodes. The population of regulatory T cells and myeloid-
derived suppresser cells were also down regulated by administration of Texo, compared to 
untreated mice. We proved that the memory B cells secreting anti-tumor IgG1, IgG2a 
antibodies existed in the bone marrow in Texo immunized mice that may be responsible 
for the long-term protection against the second lethal tumor challenge. Co-administration 
of dual toll like receptor (TLR) agonist CpG and MPL with Texo further enhanced 
dendritic cell activation and CD4+/CD8+ T cell immune response, as well as the survival 
outcome against B lymphoma. Our study proved the therapeutic role of Texos and 
unraveled the underlying mechanisms of Texo based vaccine in the established DLBCL 
model, which paved the way for the possible future clinical application of Texo in B 
lymphoma treatment.  
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2.1   Introduction 
Tumor immunotherapy aims to generative specify anti-tumor immunity that could 
suppress or eradicate the tumor without harming the healthy cells. To generate efficient 
anti-tumor immunity, three criteria needs to be fulfilled.[60] The first is to identify tumor-
specific antigens. The second challenge is to properly activate the immune system with 
stimulator. The last challenge is to deliver the antigens and immune stimulators to the APCs 
efficiently.[61] Especially, identify specific antigens for individual patient could be time 
and money consuming. In addition, even if the certain antigens are identified, whether they 
have potent immunogenicity or if they could induce long term protection is still unknown. 
Tumor derived exosomes (Texo) are nano-vesicles secreted by the tumor cells. Due 
to their cancer cell biogenesis, Texo have full spectrum of unidentified antigens, including 
proteins and nuclei acids, assembling the tumor cells.[62] Therefore, Texo provides 
endogenous antigens that allow the immune system to recognized even unidentified tumor 
antigens.[63] Moreover, Texo carry MHC class I/II molecules, co-stimulatory molecules 
and heat shock proteins that may potentially stimulate the immune system when 
encountering the immune cells. As exosomes are vesicles generated by cells to transfer 
cargoes for cell-cell and cell-environment communications, Texo are natural-derived 
delivery nano-particles and have been utilized as carriers of drugs for cancer treatment. [64]  
Based on the above characteristics, Texo showed great potential in cancer 
immunotherapy as tumor antigen source, immune-stimulatory molecules presenters and 
delivery vehicles, which could fulfill the three most challenging criteria of cancer vaccine 
design. [65] Studies have shown that Texo are a source of shared tumor rejection antigens 
 
that can cross priming cytotoxic T lymphocytes (CTLs). A phase I clinical trial showed the 
ascites-derived exosomes from cancer-beard patients in combination with the granulocyte–
macrophage colony-stimulating factor (GM-CSF) in the immunotherapy can induce 
beneficial tumor-specific CTL response. [66] However, Texo are also reported to favor the 
cancer development by supporting tumor proliferation, motility, invasion, angiogenesis, 
and pre-metastatic niche preparation. In addition, recent research implies that cancer cell–
derived exosomes may play a suppressive role in cancer-directed immune response. 
Therefore, the role of Texo in cancer vaccine is still debatable and the therapeutic effects 
as well as the fundamental immune responses driven by administration of Texo remain to 
be fully elucidated. 
Non-Hodgkin lymphomas (NHL) is a lethal disease that consists 4.2% of all the cancer 
cases, and 85% of which are B lymphoma, among which the majority are diffuse large B 
cell lymphoma (DLBCL). The most common immunotherapy for B lymphoma in clinic is 
the use of anti-B cell monoclonal antibody, such as rituximab that can specifically target 
CD20 expressed tumor cells. However, many patients may show no response to rituximab 
treatment or may develop resistance response and result in recurrence. The overall 
therapeutic effects that have achieved by monoclonal antibody treatment is to prolong the 
survival rate by 5 years. Therefore, new immunotherapy strategies remain to be developed 
for better therapeutic outcomes and Texo is a promising immunotherapeutic methods with 
the possibility for clinical transfer. However, the therapeutic effects of Texo in a clinical 
relevant aggressive diffuse large B cell lymphoma (DLBCL) model is still unknown, and 
the fundamental immune responses driven by Texo remains to be explored. 
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The purpose of this study is to testify the potential therapeutic effects of Texo in the 
DLBCL model, elucidate the fundamental immune response driven by Texo, including 
cellular/humoral anti-tumor immune response and the possible immunosuppressive effects, 
thus providing insights to possible clinic transfer of Texo-based cancer vaccine. Here, we 
established an aggressive diffuse large B cell lymphoma (DLBCL), in which lethal dose of 
A20 B lymphoma cells were injected i.p. and allowed for establishment for a week. The 
Texo, which were collected from ex vivo B lymphoma cells to better mimic the clinical 
scenarios, were then injected to the pre-established DLBCL mice, with or without the co-
administration of the TLR agonists. The survival outcome and the immune response driven 
by Texo administration were carefully studied. Our results showed that improved survival 
outcome and long-term protection against two lethal challenge of B lymphoma. Many arms 
of immune system were activated by Texo-administration including both cellular and 
humoral anti-tumor immune response. Co-administer of TLR4/9 agonists with Texo 
showed better survival outcome, compared with Texo alone, by further activate the 
immune system. 
2.2   Materials and Methods  
2.2.1 Preparation and characterization of tumor exosomes.  
A20 cells (ATCC TIB-208) were purchased from ATCC and used for exosome 
preparation and all the tumor model in this study.  Texo were collected from ex vivo tumor 
cells. To be specific, 105 A20 tumor were injected s.c. to Balb/c mice to develop a s.c.  A20 
tumor. Three weeks later, the developed solid tumor was harvested, digested to single cell 
suspension and went through magnetic cell isolation using B cell separation kit (Miltenyi 
 
Biotec) to negatively separate B lymphoma from other cells. The ex-vivo A20 cells were 
cultured in RPMI medium supplemented with 2% exosome-depleted serum for 48 hours 
and the supernatant were collected for further isolation of Texo by (ultra)centrifugation. 
To be specific, the supernatant was centrifuged at 1,200 g for 15 min, followed by 10,000 
g for 30min to remove cell debris and apoptotic bodies and the supernatants were collected.  
To precipitated exosomes, the supernatants were ultra-centrifuged at 100,000 g for 1h. The 
collected Texo were then washed twice with PBS and finally re-suspend in 200 µL PBS, 
stored in -80 °C until use. The protein content of collected exosomes was measured by 
micro BCA protein assay kit (Thermo Fisher) and was used to quantify the dose of Texo 
in the following study.  
The Texo were visualized by transmission electron microscopy (TEM) To prepare the 
samples, the Texo were fixed with 4% paraformaldehyde (PFA), stained with 2% (w/v) 
uranyl acetate for 5 mins, washed 3 times with DI water and observed by transmission 
electron microscopy. The size and zeta potential distribution of exosomes were identified 
by Zetasizer (Brookhaven Instruments). The exosomal markers were identified by flow 
cytometry. 10 µg exosomes were covalently conjugated onto 4-µm aldehyde/sulphate latex 
beads for 15min. The excess aldehyde group were blocked by excessive 100 mM glycine 
for 30 min. The exosome-beads were stained by exosomal markers CD63/CD9 and MHCI, 
MHCII and according isotypes, analyzed by BD Aria flow cytometer.  
2.2.2 Survival studies 
All the in vivo experiments with mice were approved by the institutional animal care 
and use committees at the Georgia Institute of Technology. The DLBCL model was 
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established by injection lethal dose of A20 i.p. (1×105 for the first survival study, 2×105 for 
the second survival study) in Balb/c mice (n=10). The tumor cells were allowed to 
established for 7 days, followed by three s.c. immunizations with Texo of Texo-agonists 
(dose of 10 µg Texo with or without 20 µg CpG, 30 µg MPL per injection) at day 8, 10 and 
14, respectively. For survived mice, a second lethal challenge with 2×105 A20 cells injected 
i.p. at day 76 or 74 for the first and second survival study, respectively. The survival of 
mice was monitored up to day 160. The Kaplan-Meier survival curves were generated, and 
log-rank (Mantel-Cox) tests were performed to compare survival between various groups 
using GraphPad Prism 6 software. 
2.2.3 Mechanistic studies. 
Model establishment. Mechanistic studies were performed as the same immunization 
setting as the survival study with initial i.p. injection of 2×105 A20 cells at day 1 to Balb/c 
mice (n=6), followed by three Texo immunization at day 8, 10 and 14.  On day 21, all the 
mice were sacrificed and the spleen, inguinal lymph nodes, and blood were collected and 
analyzed further for cellular and humoral immune responses using flow cytometry and 
ELISA. 
Flow cytometry analysis. To get single cell suspension for flow cytometry assay, lymph 
nodes were minced and flushed with PBS (with 2% FBS) with a 70 µm filter beneath; 
spleen were cut into pieces, digested in collagenase D (2mg/mL, Roche) for 30 min, minced 
and flushed with PBS (with 2% FBS) with a 70 µm filter beneath, followed by RBS lysis 
treatment (Biolegend). The splenocytes and lymph nodes cells were analyzed for various 
immune cell populations, CD3+CD8+ T cells, CD3+CD4+ T cells, germinal center–
 
forming B cells (B220+GL7+FAS+), Tfh (CD3+CD4+PD-1+CXCR5+), MDSCs 
(CD11b+Gr.1+), Tregs (CD4+CD25+FoxP3+), NK cells (CD3–CD49b+) using a BD 
LSRII flow cytometer following staining with specific anti-mouse antibodies. The 
antibodies for flow cytometry were purchased from Biolegend or eBioscience. 
Splenocyte restimulation studies. To stimulate the splenocytes with tumor antigens, 
tumor lysates were prepared by 4 freeze-thaw cycles of 2×108 to 4×108 A20 cells per mL, 
and the lysate was centrifuged at 12,000 g x for 20 minutes at 4°C. Splenocytes (1×106 
cells/well of 96-well plates) from immunized mice in the mechanistic study were re-
stimulated ex vivo with A20 tumor lysate (100 µg in protein content/well of 96-well plates) 
for 3 days, then stained and analyzed for IFN-γ+/IL4+, CD3+CD8+, and CD3+CD4+ T 
cells using a BD LSRII flow cytometer. Furthermore, the culture media were analyzed for 
IFN-γ and IL4 cytokines using ELISA Ready-Set-Go! Kits (eBioscience, San Diego, CA). 
Measurement of antibody levels in blood. Blood were drawn from the mice and the 
serum were collected by centrifugation. Serum antibody levels of IgG1, IgG2a and IgG2b 
were measured by ELISA using plates precoated with A20 tumor lysate (100 µg/ml). 
Optical density for various serum dilutions was measured at 450 nm. 
2.2.4 ELISPOT assay for antibody-secreting bone marrow cells. 
The bone marrow cells were separated from survived mice and seeded in 
MultiScreenHTS-IP Filter Plate (Millipore) coated with A20 tumor lysate (10 µg per well). 
After cultivation in the incubator overnight, the plates were washed with PBS and stained 
by alkaline phosphatase-conjugated secondary antibodies against mice IgG1 and IgG2a. 
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The spots were visualized by adding alkaline phosphatase substrate (Vector). The plates 
were scanned and counted on a CTL reader. 
2.2.5 ADCC assay of mice serum 
The target cells A20 were labeled with CFSE and mixed with RAW 264.7 at the ratio 
of 1:8. The serum from the survival study were added to the mixture of target/effector cells 
at 5% concentration. After 24h culture, the target/effector cells were harvested, stained 
with PI and analyzed by flow cytometry, to determine the dead cells. Target/effector cells 
without supplement of serum were served as a control. 
2.2.6 BMDC activation and MLR reaction. 
Bone marrow cells were isolated from femurs and tibias of the mice by flushing the 
bone marrow, going through the 70µm filter, followed by RBS lysis. The bone marrow 
cells were cultured in RPMI 1640 Glutamax medium (Invitrogen, Carlsbad, CA), 
supplemented with 0.25mM beta-mercaptoethanol, 1 × non-essential amino acid, 10% heat 
inactive FBS (FBS incubated at 56℃  in water bath for 30mins), 1% penicillin & 
streptomycin and 25 ng/ml mouse granulocyte macrophage colony-stimulating factor 
(GM-CSF) and 25 ng/ml IL-4 (Peprotech, Rocky Hill, NJ) for 6 days. Medium was 
changed every other day. On day 7, the cells were stained by CD11c antibody and analyzed 
by flow cytometry to determine the differentiation of DCs. The DCs acquired were 
incubated with 5 µg Texos with or without 2 µg CpG and 2 µg MPL for 48 hours. The 
BMDCs activation was evaluated by analyzing surface expression of co-stimulatory 
 
molecules CD86, MHCII, and CD40 using BD Accuri flow cytometer. The flow cytometer 
data was further analyzed with Flowjo software. 
To carry out the MLR study, the BMDCs were isolated and differentiated as described 
above. CD4+ or CD8+ naïve T cells isolated from the spleen of naïve mice using CD4 or 
CD8 MicroBeads with MACS columns and MACS separators (Miltenyi Bioetch, Germany) 
The BMDC were first activated with Texo/Texo-agonists for 48 h as described above and 
then co-cultured with CD4+ or CD8+ naïve T cells at a ratio of 1:2. After 96 h, the culture 
medium was collected and analyzed for IFN- γ and IL4 cytokines using ELISA Ready-Set-
Go! Kits (eBioscience, San Diego, CA). 
2.2.7 Statistical analysis 
Quantitative results were presented as means±standard deviation (SD). Statistical 
comparisons were performed by unpaired, 2-tailed t test to compare pairs of groups, and 
one-way analysis of variance (ANOVA) followed by Tukey tests to compare multiple 
experimental groups. Log- rank (Mantel-Cox) test was done to define significant difference 
in survival between two groups in the therapeutic studies. Values of P < 0.05 were 
considered statistically significant. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
2.3   Results  
2.3.1 Preparation of tumor-derived exosomes 
As shown in figure 2.1, the A20 tumor cells were first injected subcutaneously and 
allowed to develop into solid tumor. The tumor mass was then digested to single cell 
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suspension and B cells were specifically isolated by magnetic cell isolation in vitro. The 
exosomes were collected from the ex-vivo B lymphoma to better mimic the clinical 
scenarios. The tumor-derived exosomes (Texo) or Texo coupling with TLR 4/9 agonists 
were injected to a pre-established metastatic B lymphoma model to evaluate the possible 
anti-tumor immune response and the therapeutic efficacy. 
 
Figure 2.1 Tumor cells were harvested from mice bearing subcutaneous tumor, 
went through magnetic separation for B lymphoma cells. The ex-vivo tumor cells 
were cultured and Texo were isolated from the supernatant. Texo or Texo-agonist 
vaccine were injected to mice bearing pre-established metastatic B lymphoma. The 
in vivo immune response and survival outcome were examined. 
The TEM imaging showed the phenotype of Texo was nano-scaled vesicles. (Fig. 2.2 
A) By DLS measurement, the Texo were identified with a diameter ranging from 50 nm to 
100 nm and a negatively charged zeta potential. (Fig. 2.2 B) The Texo showed the 
expression of exosomal markers CD9 and CD63. MHCI and MHCII molecules were also 













Figure 2.2 Characterization of tumor-derived exosomes. (A) TEM photograph of 
exosomes collected from supernatants of ex vivo A20 cells. Scale bar: 50nm. (B) Size 
and zeta potential of exosomes measured by DLS. Mean ± STD. (C) Histogram of 
exosomal markers (CD63/CD9) and MHC family (MHCI/MHCII) detected by flow 
cytometry. Grey and red peaks indicate isotype and antibody staining of exosome-
conjugated latex beads, respectively. 
2.3.2 Therapeutic effects of Texo in pre-established DLBCL model. 
Texo harbored tumor specific antigens and immunostimulatory components such as 
heat shock proteins, therefore holding great therapeutic potentials as cancer vaccine. 
However, their therapeutic effects have not been testified in the pre-established DLBCL 
model. In an attempt to elucidate the anti-cancer effect of Texo alone in the DLBCL model, 
1×105 lethal dose of A20 cells were injected i.p. and were allowed to establish for one 
week, followed by the Texo injection at day 8, 10 and 14 subcutaneously as therapeutic 
vaccines. (Fig. 2.3 A) First of all, the survival curve showed that, without interference, total 
10 mice in PBS group showed 0 survival rate with a median survival of 39.5 days. For the 
group of Texo, four mice were dead at first but the survival curve showed a platform around 
day 50 with 60% survival rate. To evaluate the long-term protection of Texo vaccine, the 















i.p. at day 76. Astonishingly, the mice in Texo group that had survived the first tumor 
challenge achieved 100% survival rate in the second tumor re-challenge study. (Fig. 2.3 B) 
To make fair control, another PBS group challenged with 2×105 of tumor cells were made 
accordingly at day 76, the result showed 0 overall survival rate and the medium survival 
of 28 days. (data not shown) Compared to untreated PBS group, immunization with Texo 
has significantly prolonged the medium survival of the cancer beard mice from 38.5 days 
to more than 160 days, even under the circumstance of a second lethal tumor re-challenge. 
(Fig. 2.3 C) These results indicate that Texo alone have anti-tumor therapeutic effects on 
the established DLBCL model in this study and the long term memory of the immune 
system towards B lymphoma could be generated post the immunizations of Texo. 
2.3.3 Anti-cancer cellular immune response driven by immunization of Texo. 
 With the proof that the Texo could generate anti-cancer therapeutic effects in the 
established DLBCL mice, we then move to explore the exact immune response driven by 
Texo administration and elucidate the mechanism for the therapeutic effects of Texo 
vaccine. The mechanistic study has the same cancer model set up and Texo vaccination 
pattern as the survival study, in which 1×105 lethal dose of A20 cells were injected i.p., 
followed by three immunizations of Texo at day 8, 10 and 14 subcutaneously. At day 21, 
all mice were sacrificed and the immune response in the spleen and inguinal lymph nodes 
were evaluated. (Fig. 2.4 A) Here, the healthy naïve mice without tumor or Texo injection 
and PBS group with tumor and PBS injected were served as controls.  
To evaluate the immune response driven by Texo, we first examined the possible 
suppressive immune response, due to the debatable role of Texo in facilitating tumor 
 
 
Figure 2.3 Therapeutic anti-tumor immunity of Texo vaccine. (A) Lethal dose of 
tumor cells were injected in Balb/c mice and allowed to establish for 7 days before 
three immunizations of Texo (10 µg Texo per injection). Survived mice were re-
challenged with lethal dose of A20 tumor cells at day 76. (B)Survival of the mice 
(n=10) were measured daily. (C) Table showing median survival, log Rank P values, 
Hazard ratios for Texo compared to PBS. ** indicates P<0.01. 
growth through suppressing the immune system. To be exact, the population of myeloid 
derived suppresser cells and regulatory T cells (Tregs), which were considered being 
hijacked by the tumor cells to mitigate the immune response against tumor. The result 
showed that the granulocytic and monocytic MDSC population were not elevated in the 
spleen compared to the naïve and PBS group. (Fig. 2.4 B) As for the Tregs, the Treg 
population in PBS group showed significant up-regulation compared to naïve mice, 





































Hazard ratio (log rank)
and 95%CI of ratio
PBS ? 39.5 ?
Texo 0.0037 >160 0.2227(0.06185 to 0.5503)
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immunized with Texo, Treg population were significantly decreased compared to PBS 
group, assembling the level of Treg numbers in the healthy naïve mice in both spleen and 
lymph nodes, which indicates the tumor-associated suppressive immune response were 
reversed by Texo immunization in both spleen and lymph nodes. (Fig. 2.4 C) Therefore, 
the subcutaneous administration of Texo in our study did not lead to suppressive immune 
response but even decreased the population of Tregs that were supposed to be increased by 
tumor invasion. 
The anti-tumor cellular immune responses were then examined by re-stimulating the 
splenocytes from the mechanistic study with A20 tumor cell lysates. When re-encountering 
the antigens in vitro, the immune response of splenocytes were supposed to be magnified, 
meanwhile resembling their behavior in vivo. The result of tumor lysate re-stimulation 
study showed that Texo could induce elevated population of both IL4 secreting and IFNγ 
CD4+ T cells, compared to the other two control groups, indicating both Th1 and Th2 
immune response were activated by immunization of Texo. (Fig. 2.4 D-E) The population 
of IL4 secreting CD8+ T cells did not have significant differences between the groups, 
however, the population of IFNγ secreting CD8+ T cells were elevated in the spleen. (Fig. 
2.4 F-G) The ELISA measurements of IL4 and IFNγ concentration in the supernatants of 
the re-stimulation splenocytes were consistent with flow cytometry results: The Texo group 
has significant higher concentration of IL4 and IFNγ cytokines compared to PBS and Naïve 
group (Fig. 2.4 H-I), indicating the activated CTL immune response may be responsible 
for the therapeutic effects against B lymphoma. No significant change in NK cell 





Figure 2.4 Cellular immune responses driven by Texo vaccine. (A) Time line for 
mechanistic studies. Lethal dose of tumor cells was injected in Balb/c mice and 
allowed to establish for 7 days before three immunizations of Texo (10 µg Texo per 
injection). Mice were sacrificed on day 21, then LN and spleen were harvested for 
immunology analysis. (B) Granulocytic MDSC and monocytic MDSC in spleen. (C) 
Treg percentage of CD4+ T cells in spleen and LN. Splenocytes were restimulated 
with A20 cell lysate for 72 hours in vitro, then IL4 and IFNγ secreting CD4+ T cells 
(D-E) and CD8+ T cells (F-G) were analyzed by flow cytometry, and the culture 
medium were measured for IL4 and IFNγ concentration (H-I) by ELISA. (J) 
































































































































































































































































































































































2.3.4 Anti-cancer humoral immune response and long term protective memory B cells 
driven by immunization of Texo. 
Other than cellular immune response, the humoral response, especially the secretion 
of antibody against the tumor cell are identified as an efficient way to eradicate tumor. 
However, in the exosome vaccine study, the consequence of therapeutic outcome emphasis 
the CLT immune response but neglected the possible therapeutic humoral immune 
response. To this end, the humoral immune response including germinal center formation 
and antibody secretion driven by Texo treatment were carefully studied in the mechanistic 
study, with the same experimental setting as in figure 2.5 A. Firstly, the inguinal LNs were 
harvested and the germinal center reaction were examined by flow cytometry. Here, strong 
germinal center reactions were observed in the Texo group. Texo immunized mice showed 
significantly increased population of B200+GL7+ B cells. (Fig. 2.5A) Of those B220+ B 
cells, the GL7 and FAS double positive population was also significantly increased in Texo 
group, compared to untreated PBS group and naïve mice. (Fig. 2.5B) The population of 
follicular T cells that function as facilitating germinal center formation were also seen to 
be elevated in Texo groups, compared to untreated PBS group and naïve mice. (Fig. 2.5C) 
To evaluate the humoral immune response driven by Texo vaccination, the tumor 
specific IgG1, IgG2a and IgG2b in the blood from both mechanistic study and survival 
study were tested by IgG titter. At early time point as day 21 post tumor injection, only 
increased anti-A20 IgG1 secretion were observed in the mice serum. (Fig. 2.5D) However, 
no differences were observed in anti-A20 IgG2a and IgG2b secretion in the serum among 
the three groups at day 21 post tumor injection. (Fig. 2.5E-F) Interestingly, the elevated 
anti-A20 IgG1, IgG2a and IgG2b level in the serum was detected at a later time point at 
 
day 160 post tumor injection, when compare the serum from those survived mice in the 
Texo group with the healthy naïve group and PBS groups from the first survival study. (Fig. 
2.5G-I)  
As shown that the tumor specific antibodies are highly detectable for relatively long periods 
(Fig. 2.5G-I), thus it is speculated that the observed antibody titer might be maintained by 
antibody-secreting plasma B cells. The bone marrow cells of the survived mice in the Texo 
group were analyzed by ELISPOT for A20 specific IgG1 and IgG2a. The three mice of 
PBS mice were served as control. The result showed the existence of A20-speicific IgG1 
and IgG2a antibody secreting memory B cells in the bone marrow for Texo groups, while 
none spots were observed in the control PBS mice. (Fig. 2.5J-K) To further confirm that 
the antibodies had cytotoxic effects against tumor cells, the blood serum were added to the 
co-culture of A20 cells and macrophage/splenocytes and the antibody-driven cell 
cytotoxicity (ADCC) of the serum against A20 cells were evaluated by PI staining. It was 
found that only the serum from survived mice in Texo group showed significant promoted 
ADCC effects against A20 cells, compared with serum from PBS group. (Fig. 2.5L) On 
the contrary, the serum from dead mice in Texo group showed no significant differences 
with PBS serum. Based on the above data, it could be concluded that the Texo could induce 
the generation plasma B cells that secrete anti-tumor antibodies. Therefore, the observed 
memory B cells in the bone marrow generated post Texo immunization might be 





Figure 2.5 Humoral responses for Texo vaccine. Graphs showing frequencies of 
germinal center (A, B) and TFH cells (C) in the draining LN. The antibody level of 
IgG1, IgG2a, IgG2b against A20 tumor lysate in the serum at day 21 in the 
mechanistic study (D-F) (time line is the same as in figure 3) and at day 160 of 
survived mice in Texo group in survival study (G-I) (PBS mice serum were 
harvested at the day they were dead). The plot showing bone marrow cells that 
secreting IgG1 (J) and IgG2a (K) antibodies against tumor lysates using ELISPOT 
at day 160 of survived mice in Texo group in survival study (PBS mice were from 
rechallenge survival study at day 53 post tumor injection). (L) Graph showing 
cytotoxicity of serum against A20 cells in the survival study. 1% serum were applied 
to the co-culture of A20 cells and macrophages at the ratio of 1:8. *P<0.05, 
































































































































































































































































































































2.3.5 Co-administration of TLR4/9 agonists with Texo enhanced anti-tumor immunity. 
 TLR agonist could facilitate non-specific immune activation by binding to the TLR 
on the immune cells. It has been reported that co-administration of two TLR agonists may 
generate synergistic activation effects on the immune system compared to one alone. In 
order to further activate the observed Th1 and Th2 immune response driven by Texo 
immunization (Fig. 2.6D-I), the MPL and CpG were co-administer with the Texo to further 
improve the therapeutic effects against the DLBCL. In the second survival study, a more 
aggressive DLBCL model were adopted with 2×105 tumor cells injected i.p., doubled the 
initial tumor cell number in the first survival study. Still, the injected tumor cells were 
allowed to establish for a week without any interference. (Fig. 2.6A) In the more aggressive 
model, Texo alone showed limited therapeutic effects. The median survival is day 30 for 
Texo group, which had no significant differences with PBS group with a median survival 
of day 29. However, the Texo-agonists showed significant improvement on mice survival 
with a median survival of day 43.5 compared with PBS group. The Texo-agonists group 
showed 30% survival rate at the end of the study, whereas the Texo group 10% and PBS 
0. (Fig. 2.6 B, C) Worth mentioning, the all survived mice in Texo-agonist group and Texo 
group had survived the second lethal challenge of tumor cells at day 74, indicating again 
the immunization of Texo could generate long term protection against the B lymphoma. 
To elucidate the effects on the immune activation and the improved therapeutic 
effects of Texo-agonists, the bone marrow derived dendritic cell (BMDC) maturation and 
the T cell immune response in the mixed lymphatic reaction (MLR) were evaluated in vitro. 




Figure 2.6 Therapeutic efficacy of Texo-adjuvant vaccine. (A) Lethal dose of tumor 
cells were injected in Balb/c mice and allowed to establish for 7 days before three 
immunization of Texo-adjuvant vaccine (10 µg Texo/20 µg CpG/30 µg MPL/1 mg 
Alum per injection). Survived mice were re-challenged with lethal dose of A20 
tumor cells at day 74. (B)Survival of the mice (n=10) were measured daily. (C) Table 
showing median survival, log Rank P values, Hazard ratios for Texo-adjuvant 
groups compared with PBS. ** indicates P<0.01. 
population of MHCII+CD86+ and MHCII+CD40+ BMDC. The co-administration of MPL 
and CpG further enhanced the BMDC maturation maker expression. (Fig. 2.7 A, B) The 
IL12p70 secretion in the supernatant of BMDC culture showed the similar trends. (Fig. 2.7 
C) The primed DCs by Texo or Texo-agonists were then co-cultured with CD4+ T cells or 
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CD8+ T cells isolated from spleen and the supernatant of the MLR were measured for IL4, 
IFNγ concentration. The IL4 concentration was significantly elevated in the CD4+ T cell 
MLR and CD8+ T cell MLR for Texo-agonists group compared to Texo alone and PBS 
group. (Fig. 2.7 D, F) Significant increase of IFNγ was observed in both Texo and 
Texo+agonists group compared with PBS group in the CD4+ T cell MLR and CD8+ T cell 
MLR. (Fig. 2.7 E, G) 
 
 
Figure 2.7 Texo-adjuvant vaccine enhanced BMDC maturation and T cell immune 
response. Graph showing percentage of CD11c+ BMDC expressing both MHCII 
and CD86 (A), both MHCII and CD40 (B), and the IL12p70 (C) concentration in 
the supernatant measure by ELISA. The IL4 (D, F) and IFNγ (E, G) secretion in the 
supernatant of isogenic MLR study between BMDCS and CD4+ T cells, or between 
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2.4   Discussion 
Cancer immune therapy is a modern treatment method with the promising potential 
to completely cure the cancer. Especially, the tumor-antigen specific therapeutic vaccines 
allow the generation of tumor-specific anti-cancer immunity while without endangering 
healthy tissues. However, the tumor-antigen specific therapeutic vaccines often require the 
identification of certain antigens, which is time and money consuming, thus largely limited 
their clinical applications. Texo have inherited similar spectrum of tumor specific antigens, 
allowing the immune system to identify multiple antigens for an individual patient. Their 
components of immune-active molecules and the structure of nano-vesicles meant for 
cargo delivery contribute to the possibilities for Texo to be used as cancer vaccine. [67-
69]However, the role of Texo in cancer treatment is still debatable as some studies claim 
the Texo have the properties to support cancer growth. Therefore, the purpose of this study 
is to testify the therapeutic effects of Texo immunization and comprehensively elucidate 
the immune response driven by Texo administration, ultimately paving the way for Texo-
based cancer vaccine for B lymphoma.  
In the survival study, three experimental designs were adjusted in order to better mimic 
the scenario in the clinical settings for B lymphoma. First, the Texo were collected from 
ex vivo A20 B lymphoma cells that had been established in vivo, instead of A20 cell lines. 
Second, a pre-established aggressive DLBCL model was adopted, in which the lethal dose 
of A20 cells were injected i.p., and allowed to establish for 7 days in vivo, followed by 
immunizations of Texo. Compared to s.c. injection of B lymphoma cells or vaccine 
immunization even before tumor establishment, our experimental setting is more clinical 
relevant. Third, in a very later time point post the first tumor challenge, the survived mice 
 
were re-challenged with a second lethal dose of tumor cells and the survival curves were 
monitored for upto 160 days. This experimental setting focused on the long-term protection 
against tumors, which is needed by clinical treatment in case of possible tumor recurrence. 
By three s.c. injections, the Texo alone with very low dose (10 µg per injection) showed 
impressive long-term immune protection against two lethal tumor challenges and achieved 
as high as 60% survival rate and >160-day median survival in the lethal B lymphoma model, 
compared to untreated PBS group with 0 survival rate and 39.5-day median survival. (Fig. 
2.3) Though many exosome-based cancer vaccines in research or clinic focused on 
dendritic cell derived exosomes (Dexo), the process of pulsing antigens to patients’ 
autologous DCs is time and money consuming, also complicated the clinical operating 
process. Since the immunogenicity of Texo has been proved here and in many other studies, 
direct injection of Texo to defeat cancer might be an alternative option for Dexo-based 
cancer vaccine and worth being pushed forward in clinic. 
The following mechanistic study has shown the activation of both cellular and humoral 
immune response that may underlie the therapeutic effect of Texo against B lymphoma. It 
has been reported that both CD8+ and CD4+ T cells are required for the therapeutic effect 
of Texo in the established lymphoma model. And our study has further implicated the Texo 
driven T cell immune response. First of all, it is very interesting to see that the Texo 
immunization leads to the simultaneous induction of IFN-γ mediated Th1 and IL4 mediated 
Th2 immune response. (Fig. 2.4 D, E) The Texo could also activate IFN-γ secreting CD8+ 
T cells, indicating the potential antigen-specific CTL responses driven by Texo. The strong 
humoral immune responses were also observed by activation of germinal center reaction 
in the lymph nodes, inducement of the anti-tumor antibody secretion in the blood and 
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generation of anti-tumor plasma B cells in the bone marrow. (Fig. 2.5) Especially, high 
level of anti-tumor IgG2a, IgG2b and IgG1 were found at day 160 in the blood immunized 
with Texo. Since the IgG1 antibody secretion is related to Th1 immune response, while the 
IgG2a and IgG2b secretion is mediated by Th2 immune response, the antibody secretion 
pattern is consistent with our previous results showing activation of both Th1 and Th2 
immune response. The existence of plasma cells secreting anti-tumor antibodies in the bone 
marrow as well as the ADCC effects of blood serum further proved the close relationship 
between humoral immune response and long-term protection against tumor induced by 
Texo injections. Our study has revealed the potential therapeutic role of humoral immune 
response driven by Texo in B lymphoma treatment for the very first time. As many studies 
focused CTL immune response to clear the tumor cells, our study emphasizes the 
equivalent importance of anti-tumor humoral immune response in B lymphoma treatment. 
TLR agonists could specifically bind to the TLR on the immune cells and active full 
spectrum of immune responses based on the signaling mechanisms of certain TLR agonist. 
CpG and MPL are TLR9 and TLR4 agonists, respectively. They are potent adjuvants with 
low toxicity and are widely used in clinical trials in cancer immunotherapy. It has been 
reported that CpG could induce strong type 1 immune responses, while MPL can induce 
both tumor-specific humoral and cellular immune responses. Moreover, co-administration 
of dual or multiple adjuvants are proved to be even more potent compared to one in cancer 
immunotherapy. Therefore, the TLR agonists were added to the formulation of the Texo 
based cancer vaccine in our study to further prompt the observed cellular and humoral anti-
cancer immune responses. In a more aggressive DLBCL model, in which the initial injected 
tumor cell number were doubled, when Texo alone showed limited therapeutic effects, the 
 
co-administration of Texo and TLR4/9 agonists showed supreme effects on improving the 
cancer mice survival. Other adjuvants, including the Alum and PLGA micro-particles that 
could absorb exosomes by static interaction, were also tested in the survival study, however 
achieved no therapeutic effects. (data not shown) Therefore, the adoption of TLR agonists 
as adjuvant in Texo-based adjuvants are recommended to treat B lymphoma in the future 
research and clinic study. Administration of TLR4/9 agonists has further activated multiple 
effector arms of immune system, including bone marrow dendritic cell maturation, CD4+ 
and CD8+ T cell immune response in vitro. (Fig. 2.7) Surprisingly, Texo alone did not 
induce Th2 immune response in MLR in vitro though showed strong Th2 immune response 
in mechanistic study in vivo. The possible reason could be the Texo may activate the T cell 
immune cells by not only APC-T cell pathway but direct interrelation with T cells. 
However, the addition of TLR4/9 agonists has tremendously activated the Th2 immune 
response in the MLR. Regardless of the deeper mechanism of Texo-TLR4/9 driven 
immune response, which needs further examination in vivo, the co-administration of 
TLR4/9 with Texo holds the potential to further activate the immune system and achieve 
improved therapeutic effects in aggressive B lymphoma model compared to Texo alone. 
To conclude, our study confirmed the promising therapeutic potential of Texo-based 
cancer vaccine in the DLBCL model and comprehensively evaluated the mechanism of the 
anti-cancer immunity driven by Texo. The Texo vaccine provides long-term immune 
protection against pre-established DLBCL model. The immunization of Texo activate 
many effective arms in the immune system, including cellular immune responses and anti-
cancer humoral immune response. Especially, the plasma B cells with the capacity of 
secreting anti-tumor antibodies may be responsible for the long-term protection effects 
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caused by Texo. The formulation of Texo plus TLR4/9 agonists showed enhanced 
therapeutic outcome and provide options for adjuvant selection in the Texo-based cancer 
vaccine. Our study elucidated the mechanism and proved the therapeutic effects of Texo-
based cancer vaccine that paved the way for the possible translate of Texo in the clinical 




CHAPTER 3.   FUNCTIONAL FIBROUS SCAFFOLDS FOR 
POTENTIATING IMMUNOMODULATORY PARACRINE 
ACTION OF MESENCHYMAL STROMAL CELLS 
While the studies on the material interaction with mesenchymal stromal cells (MSCs) 
have been mainly focused on the ability of materials to provide environment to regulate 
cell viability, proliferation or differentiation, the therapeutic effects of MSC-material 
constructs may result from the secretion of immunomodulatory and angiogenic cytokines 
from MSCs. Here, electrospun scaffolds composed of fibers in random, aligned and mesh-
like patterns were fabricated, and the paracrine behavior of adipose-derived MSCs (Ad-
MSCs) on the scaffolds were investigated in comparison to the cell culture via conventional 
microplates. It was found that the Ad-MSCs on the electrospun fibers produced 
significantly higher levels of anti-inflammatory and pro-angiogenic cytokines compared to 
those cultured on microplates. The enhanced modulatory effects of the secreted products 
of Ad-MSCs on fibrous electrospun scaffolds were also proven in the cultures of 
endothelial cells and the LPS-stimulated macrophages, with three types of scaffolds 
showing distinct influences on the paracrine function of Ad-MSCs. In a skin excisional 
wound-healing model in rat, the conditioned medium collected from the MSC-scaffold 
system accelerated the wound closure, promoted the macrophage recruitment and enhanced 
the polarization of macrophages toward the pro-healing phenotype in the wound bed. Our 
study demonstrates that the fibrous topography of scaffolds is a key material property that 
modulates the paracrine function of cells. The discovery elucidates a new aspect of material 
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functions, laying the foundation for developing scaffold materials to promote tissue 
regeneration/repair through guiding the paracrine signaling network. 
3.1   Introduction 
Mesenchymal stromal Interestingly, both Th1 and Th2 immune response were activated 
simultaneously. As many study emphases the Th1 biased immune response is the key to 
drive specific tumor cell killing effects, the observed Th2 immune response provide new 
angels to re-evaluate the function of T helper cell activation. cells (MSCs) are multipotent 
adult stem cells capable of differentiating into multiple lineages, including osteoblasts, 
adipocytes, chondrocytes and myoblasts, under different stimuli and culture conditions.[21] 
In recent decades, MSCs are one of the most widely investigated cell types in regenerative 
medicine and have achieved promising therapeutic results in treating graft-versus-host 
disease, myocardial infarction, cerebral stroke and wound healing etc.[19, 20, 22] However, 
studies have shown that the multi-lineage potential of MSCs may contribute little to their 
therapeutic effects. Instead, the paracrine products of MSCs could exhibit multifaceted 
functions including immunomodulation, angiogenesis, anti-apoptosis, anti-scarring, 
chemoattraction and modulating local stem and progenitor cells.[21, 70] In particular, the 
trophic factors, such as vascular endothelial growth factor (VEGF), hepatocyte growth 
factors (HGF) and basic fibroblast growth factor (bFGF), secreted by MSCs could promote 
vascularization in the wound area.[71, 72] The anti-inflammatory molecules, including 
indoleamine-2, 3-dioxygenase (IDO), prostaglandin E2 (PGE2) and tumor necrosis factor 
α (TNF-α)-stimulated gene 6 (TSG-6), would modulate both innate and adaptive immune 
responses away from scarring but towards regeneration.[23, 70, 73] Taken together, MSCs 
 
hold promise to serve as a vital cellular modulator by sensing the environment and creating 
an orchestrated network of molecules to promote the tissue repair/regeneration process. 
Scaffold is a key component in the concept of tissue engineering, which works as a 
substrate for cells to attach and grow.[74] With the microstructures, surface 
morphology/chemistry and mechanical properties, the intriguing function of a scaffold lies 
in its ability to generate tailored microenvironment that may guide the cell behavior 
through specific cell-material interactions. Under the assumption that scaffolds may be 
designed to promote the differentiation of MSCs during cell transplantation to supplement 
the injured tissue with functional cells, numerous studies have been carried out in this 
aspect to understand/engineer the bioactivity of scaffolds.[75-79] Yet little is known about 
how scaffolds and the material topographical properties might affect the paracrine function 
of MSCs, despite the pivotal role of the secretory products of MSCs in mediating the local 
signaling processes in vivo. In this study, we thereby are interested in designing 
experiments to probe two fundamental questions: 1) how the secretory behavior of MSCs 
would be altered upon the contact with a fibrous scaffold and 2) whether this new aspect 
of cell-material interaction has implication for tissue repair/regeneration settings. In 
particular, we intend to investigate the profile of the pro-angiogenesis and anti-
inflammatory factors secreted by MSCs, as these two categories of cytokines may 
participate in key tissue repair/healing processes and are potent factors that may improve 
the therapeutic effects of MSCs in vivo.  
To this end, we here selected electrospun fibers (EFs) to probe the relationship between 
fibrous microenvironment and the MSC paracrine activity. Because of the advantages such 
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as the convenient fabrication process, the wide choice of materials and precision control 
over fiber parameters, EFs constitute an important category of scaffold materials that haven 
been intensively studied in tissue engineering. [80-82] In particular, by mimicking the 
natural extracellular matrix, the micro-/nano-fibers have been found to provide distinct 
contact cues to modulate cell activities, including supporting cell proliferation, promoting 
the stemness and maintaining pluripotency of stem cells.[83, 84] In addition, the 
orientation/alignment of fibers has also been shown to generate topography-induced cues 
to promote Schwann cell maturation, vascular endothelial cell growth, myotube formation 
and MSC differentiation. [77-79, 85, 86] 
Here, polycaprolactone (PCL) EFs with three different alignment characteristics were 
fabricated as model scaffold materials. The effects of the fibers on rat adipose-derived 
MSCs (Ad-MSCs) to produce pro-angiogenic and anti-inflammatory paracrine factors 
were investigated. The function of these paracrine factors was further studied through 
collecting conditioned-medium (CM) from different culture systems and applying it to 
cultures of endothelial cells and macrophages in vitro and a skin wound-healing model in 
vivo. Our study suggests that the fibrous topographical structure has profound effects on 
the secretory behavior of Ad-MSCs and the cells tend to produce cytokines that are capable 
of promoting angiogenesis, immunomodulation and tissue healing processes. The 
discovery on the relationship between cell paracrine function and materials reveals a new 
aspect of material properties that has not been systematically studied before. The study also 
suggests the potential approach to modulating of the paracrine signaling network through 
design of functional scaffolds to improve cell-based regenerative therapy.  
 
3.2   Materials and Methods  
3.2.1 Materials and reagents 
Ultrapure water ≥18 MΩ was derived from deionized water though a Milli-Q 
system (Millipore, Billerica, MA). Polycaprolactone (PCL) and lipopolysaccharide (LPS) 
were obtained from Sigma-Aldrich (Milwaukee, WI). QuantiT™  PicoGreen® dsDNA 
Assay Kit, TRIzol kit, Dulbecco’s phosphate buffered saline (DPBS) and cell culture 
reagents were purchased from Invitrogen (Carlsbad, CA, USA) unless otherwise specified. 
Solution Cell Activity Assay (MTS) systems were from Promega (Madison, WI). Matrigel 
was from BD Biosciences (San Jose, CA, USA). 4',6-diamidino-2-phenylindole (DAPI) 
and Rhodamine Phalloidin was obtained from the ThermoFisher (MA, USA). Human 
umbilical vein endothelial cells (HUVECs), Endothelial cell medium (ECM), endothelial 
cell growth supplement (ECGS) were purchased from ScienCell (Carlsbad, CA). Rat 
adipose-derived mesenchymal stromal cells (Ad-MSCs) were purchased from Cyagen 
Biosciences Inc (Santa Clara, CA, USA). The murine-macrophage cell-line RAW 264.7 
were obtained from the Cell Culture Center of the Institute of Basic Medical Sciences 
(Beijing, China). Suppliers of other chemicals, biological reagents, and equipment were 
specified below. 
3.2.2 Cell culture 
All cells were cultured at 37°C under humidified atmosphere with 5% CO2. The Ad-
MSCs were cultured in minimum essential medium α (MEM-α) supplemented with 10% 
fetal bovine serum (FBS), 0.4% penicillin/streptomycin (P/S), without further supplement 
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of growth factors. For the collection of conditioned media, the MSCs were cultured in FBS-
free MEM-α for a prescribed period of time.  The Ad-MSCs between passage 3 and 5 were 
used for the following experiments. The human umbilical vein endothelial cells (HUVECs) 
were maintained in endothelial cell medium (ECM) supplemented with 5% FBS, 1% (P/S) 
solution and 1% ECGS. RAW264.7 macrophages (MΦ) were cultured in DMEM 
supplemented with 10% FBS and 1% P/S. To detach cells from the culture plates, Ad-
MSCs and HUVECs were treated with trypsin/EDTA solutions, while macrophages were 
pipetted repeatedly to induce the detachment. 
3.2.3 Fabrication of fibrous scaffolds 
Electrospun fibrous scaffolds were prepared from polycaprolactone (PCL) solution. 
15% w/v PCL was dissolved in a mixture of CHCl3 and dimethylformamide at the volume 
ratio of 9:1. After stirring for 3 h until PCL was completely dissolved, 1 mL of the solution 
was loaded into a syringe with a blunt-ended stainless steel needle. The feeding rate and 
the applied voltage were controlled at 0.5 mL/h, 12kV, respectively. The collection 
distance for random EF (REF) and mesh-like EF (MEF) was 14 cm and for aligned EF 
(AEF) 10 cm. The REF was collected on a flat plate, the MEF on a copper mesh, and AEF 
through a rotating cylinder at speed ~3000r/min. The EF membranes were cut into 
predefined sizes and shapes manually. For sterilization, EF membranes were rinsed with 
75% ethanol solution for 30 mins and then washed with sterilized DI water for three times 
and air dried in bio-safety cabinet (Thermo, Germany). The EF scaffolds were exposed 
under ultraviolet radiation for 30 min on each side in the bio-safety cabinet for further 
sterilization and were kept in sterile dishes at 4°C until being used. 
 
3.2.4 SEM and confocal imaging 
Topographical features of the scaffolds were examined by scanning electron 
microscopy (SEM) (S-4800, Hitachi, Japan). For the measurement of fiber diameter, 300 
fibers were randomly selected in the SEM pictures and the diameter was calculated by 
ImageJ software. To examine the cell morphology on the scaffolds, 2×104 Ad-MSCs were 
seeded on the scaffolds for 24 h. The scaffolds were washed with PBS, and the attached 
cells were fixed in 2% glutaraldehyde overnight at 4°C. Samples were then dehydrated by 
rinsing in ethanol solution with series of concentration (from 30% to 100%, v/v) for 15 min 
at each step. Once dried, the samples were examined via SEM. For fluorescent confocal 
imaging, scaffolds seeded with Ad-MSCs were fixed overnight by 2% paraformaldehyde 
(PFA), and the cells were stained with Rhodamine Phalloidin for 1 h and then DAPI for 5 
min. The stained cells were pictured by A1R-si confocal microscope (Nikon, Japan) 
3.2.5 Real time PCR assay  
All gene expression assays, including the expression of paracrine products and cell 
differentiation and stemness markers were performed through the same protocol. 1×105 
Ad-MSCs were seeded on polystyrene 24-well plates or on circular scaffolds trimmed with 
the same size as the microwell and supplied with MEM-α medium supplemented with 2% 
FBS and 1% P/S. For the nuclear factor-𝜅B (NF𝜅B) inhibition study, the medium was 
additionally supplemented with 1 mM NF𝜅B inhibitor, pyrrolidinedithiocarbamic acid, 
ammonium salt (PDTC) (Sigma-Aldrich, Milwaukee, WI). After cultivation for 24 h (or 7 
d), the total RNA of these samples was extracted using the TRIzol kit according to the 
manufacturer’s instructions. The total isolated RNA was reverse transcribed with 
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TransScript First-Strand cDNA Synthesis SuperMix (Transgene, Beijing, China). The gene 
expression levels were analyzed using the SYBR Green real-time PCR method and were 
quantified using the Bio-Rad CFX connect real time PCR system (Bio-Rad, Hercules, CA). 
Primers were ordered from Sangon (Shanghai, China). The sequences of primers for qRT-
PCR were listed in Table 1 in the supplementary information (SI). All gene expression 
values in one sample were normalized to the GAPDH level. Relative expression was 
calculated using the comparative Ct method. The mean minimal cycle threshold values 
were calculated from triplicate reactions.  
3.2.6 Cell proliferation and metabolic assays 
Ad-MSCs cultured on different substrates for 1-5 day were examined for metabolic 
activities and DNA contents through the MTS assay and picogreen staining, respectively. 
For the MTS assay, the supernatants in each cell culture well were removed, and 20 µl 
CellTiter96 aqueous one solution, diluted 5 times with fresh medium, were added. The 
plates were kept at 37 ºC in the dark for 2 h. The absorbance of the supernatant was 
measured at 490 nm using the SpectraMax M2 microplate reader. To determine the DNA 
contents in each sample, the cells cultured on the EF scaffolds were lysed using 0.1% Triton 
X-100 solution at 4 ºC overnight to obtain the DNA sample solutions. 100 µl of DNA 
sample solutions were mixed with an equal volume of PicoGreen reagent according to the 
manufacturer’s protocol. After 5 min, the fluorescence was measured using the microplate 
reader (excitation: 480 nm; emission: 520 nm) to determine the DNA contents of the 
samples and the cell numbers were then calculated based on the standard curve. To 
determine the metabolic activity on the single cell level, the value of MTS assay was 
normalized to the cell number determined by the DNA content assay. 
 
3.2.7 Assay of paracrine products 
1×105 Ad-MSCs were seeded on 24 well plates or 1.9 cm2 scaffolds and 
supplemented with 1 mL culture medium. To collect the CM, cells were first cultured in 
complete MEM-α medium for 12 h, then washed three times with PBS and supplemented 
with FBS free MEM-α medium to exclude the influence of serum in the culture. After 24 
h cultivation, the supernatant was collected and centrifuged at 5000 rpm to remove the dead 
cells and cell debris. (When the cells were maintained under the serum-free conditions, the 
culture was conducted for a maximum of 24 h to ensure that the CM was collected from 
healthy cells.) The cells remained in the MP or scaffolds were fixed with 2% PFA and 
stained with 0.5 µg/mL DAPI for 10 min. Fluorescence images fully covering the 
microwell were captured by an IX71 fluorescence microscope (Olympus, Japan), and the 
number of cells in each well was counted based on DAPI staining without repetition by 
ImageJ software. The concentration of all the CM samples was then adjusted with MEM-
α to make sure the secretory products measured in different samples were generated by the 
same number of cells. Enzyme-Linked ImmunoSorbent Assay (ELISA) analyses for PGE2, 
TGF-β, VEGF, bFGF and HGF (R&D) in CM were then performed following the 
manufacturer’s instructions. The nitric oxide in conditioned medium was measured by 
colorimetric Griess reaction kit (Beyotime, China). 
3.2.8 Expression profiling of LPS-induced macrophages 
The macrophage cell line raw264.7 were seeded in 24-well culture plates at 2×105 
per well for 24 h, followed by adding 500 ng/ml LPS to stimulate macrophages. After 1 h, 
the LPS-containing supernatants were removed and cells were gently washed with DPBS 
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for three times. The macrophages were then treated with 50% complete DMEM and 50% 
CM. The concentration of CM samples was adjusted according to the Ad-MSCs number 
as described above. After 8 h treatment, the total RNA of macrophage was extracted from 
each sample and the relevant gene expression was measured by real time qPCR assay. 
Samples supplemented with or without LPS, both without CM treatment, were served as 
the positive or negative controls, respectively.  
3.2.9 HUVEC proliferation and tube formation assay 
For the HUVEC proliferation assay, the HUVECs were cultured in complete ECM 
medium for 6 h for cells to fully adhere to the microplates. The medium was then changed 
to a serum-free ECM containing 1% P/S and 1% ECGS to starve the cells for 12 h. The 
media were then replaced with the ECM (containing 2% FBS and 1% P/S) and CM at 1:1 
volume ratio. The CM were prepared and adjusted according to the Ad-MSCs number as 
described above. Before each step of changing the medium, cells were washed with sterile 
DPBS gently for three times. After 24 h, the cells fixed in 2% PFA and stained with 0.5 
µg/mL DAPI for 10 min. The cell number was counted based on the DAPI staining as 
described above. For the HUVEC tube formation assay, 1×104 HUVECs were seeded onto 
the Matrigel films in 96-well plates, treated with 50% CM and 50% ECM supplemented 
with 2% FBS and 1% P/S. Cells were incubated for 6 h and imaged under bright-field 
microscopy. Tube length was quantified by ImageJ software. The HUVECs cultured in the 
ECM supplemented with 2%FBS, 1% PS and 1% ECGS, and the ECM with 2% FBS and 
1% P/S lacking ECGS, served as the positive and negative control, respectively, in both 
HUVEC proliferation and tube formation assay. 
 
3.2.10 Rat skin excisional wound healing model 
All procedures were performed in accordance with the regulations approved by the 
Institutional Animal Care and Use Committee (IACUC) of Peking University. Sprague–
Dawley male rats (Vitalriver, Beijing, PR China) weighing 290–320g were anesthetized; 
two 7-mm diameter round full-thickness excisional skin wounds were created on each side 
of the midline using a biopsy puncher following the hair removal from the dorsal skin. A 
donut-shaped silicone splint was glued to the skin using the superglue with the wound 
centered in the splint. The splint was used to stabilize the wound and avoid contraction, 
making wound area comparable. For in vivo experiments, each CM sample was collected 
as described above and further concentrated (nearly 30 times) by ultrafiltration with a 3 
kDa molecular weight cut-off filter (Millipore, America) following the manufacturer’s 
instructions. Each wound then received 200 µL solutions of the CM collected from MSC-
MEF or MSC-MP, or just blank MEM-α in a randomized order. In the application of the 
solutions, 150 µL CM was injected subcutaneously around the wound and 50 µl CM was 
topically smeared onto the wound bed. Finally, a Tegaderm (3M, MN, USA) was placed 
over the wounds to keep the wounds clean and avoid contamination. Digital photographs 
of the wounds were taken at day 0, 4, 7, and the wound area was measured by the ImageJ 
software. The wound area was not calculated after day 7 because of the fall-off of the splint. 
The percentage of the wound closure was calculated as: (area of original wound - area of 
actual wound)/area of original wound × 100%. 
3.2.11 Histology and immunostaining 
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Rats were sacrificed at day 7 or day 14. The skin tissues including the wound and the 
surrounding skin were harvested, and was cut into two parts from the middle line for 
histology observation. The dermal specimens were then fixed with 10% formaldehyde, 
embedded in paraffin and cut into sections with thickness of 5 µm. The sections were 
stained with hematoxylin and eosin (H&E) or Masson’s trichrome (MT) before imaged by 
a light microscope (Olympus, Japan). For the immunohistochemical staining, the tissue 
slides were deparaffinized followed by antigen retrieval in boiling citrate buffer (10 mM 
citrate, pH 6.0) for 24 min. Non-specific binding was blocked by incubation with 5% 
donkey serum (Jackson, 017-000-121) for 30 min at room temperature. The sections were 
decanted and incubated with primary antibodies overnight at 4°C. The primary antibodies 
against the pan-macrophage marker CD68 (mouse anti-rat CD68, Abd Serotec, 
MCA341GA), and the M2 macrophage marker CD206 (goat anti-human CD206, Santa 
Cruz, sc-34577) were applied to the specimen. The sections were then washed and 
incubated with the two fluorescently conjugated secondary antibodies, donkey anti-mouse 
Alex Fluor-555 (Invitrogen, A31570) and donkey anti-goat Alex Fluor-488 (Jackson, 705-
545-147), for 1 h at room temperature. The nuclei were labeled with DAPI, and the slides 
were covered with the fluorescent mounting medium (Boster，AR1109) for confocal 
microscopy imaging. The macrophage cell number of different types was counted by 
ImageJ software based on the color of fluorescent dye. 
3.2.12 Statistical analysis 
Quantitative results were presented as means±standard deviation (SD). Statistical 
comparisons were performed by one-way analysis of variance (ANOVA) followed by 
 
Holm-Sidak tests to compare selected data pairs. Values of P < 0.05 were considered 
statistically significant. 
3.3   Results  
3.3.1 Preparation of electrospun fibrous matrices and culture of Ad-MSCs 
As shown in figure 3.1, three types of EF materials, showing random, aligned and a 
mesh pattern, were first prepared, which were designated as REF, AEF and MEF, 
respectively. The materials were seeded with Ad-MSCs and the paracrine products from 
different culture system were analyzed through profiling the gene expression and protein 
secretion from the cells. The function of the paracrine products was investigated by 
collecting the CM and applying them to the in vitro cultures of endothelial 
cells/macrophages and an in vivo skin wound healing model. In all the experiments, the 
cells cultured on the polystyrene microplate (MP) were used as a control for comparison 
to understand how the materials with fibrous topological characteristics may affect the 
paracrine secretion of MSCs. 
In Figure 3.2, it is shown that the EF scaffolds fabricated through electrospinning 
processes using different collectors had distinct morphologies. (Fig. 3.2 A-C) While the 
REF and AEF contained random and aligned fibers, respectively, the MEF collected using 
the copper mesh as a collector was made of bundled fibers oriented vertically in lattice 
patterns with the grid length at 830 µm. It is noted that the loose fibers deposited inside the 
grid were also vertically crossed. By tuning the electrospinning parameters, the fiber 
diameters in the three types of EFs were controlled at the scale of 1 micrometer in three 





Figure 3.1 The experimental design to investigate the influence of the fiber 
morphology and fiber orientation on the paracrine secretion and function of Ad-
MSCs. The scaffolds for cell culture included electrospun fibers in random, aligned 
and a mesh organization, which were designated as REF, AEF and MEF, and the 
cultures on EFs were compared to the Ad-MSCs cultured on polystyrene microplate 
(MP). 
When the Ad-MSCs were cultured on the three EF scaffolds, the cells could all 
adhere and grow. Both the SEM and confocal microscopic studies show that the 
cytoskeletons of the Ad-MSCs following 24h h culture were random or oriented depending 
on the topology of the underlying scaffold. (Fig. 3.2 D-I) On the REF, the cells were 
basically round with protruding edges, likely resulting from the cytoskeletons stretched in 
different directions (Fig. 3.2 D, G). On both AEF and MEF the cells were relatively 
elongated and oriented on top of the aligned or bundled fibers (Fig. 3.2 E-F, H-I), 
respectively. In particular, the majority of the Ad-MSCs adopted two vertical directions on 
 
MEF, both on the grid lines on the fiber bundles and inside the grids on the loose fibers. 
(Fig. 3.2, F1-3 and A2) 
When the metabolic levels were examined through the MTS assay, it was shown that 
the cells seeded on the EF scaffolds were metabolically more active than the cells on 2-D 
MP on day 1, and the metabolic levels then dropped and became similar to the cells cultured 
on microplates. In studying the cell proliferation levels, there was no statistical difference 
among the cells on the three types of EFs (Fig. 3.2 J). Quantification of the cell number 
indicates that the cells proliferated at a similar rate as those grown on the MP. (Fig. A3) As 
the Ad-MSCs are multipotent with differentiation capabilities toward connective tissues, 
the gene expression of the adipogenic, chondrogenic and osteogenic markers were 
analyzed. Compared to the gene expression at day 0, no genes were found to express at 
elevated levels up to day 7, suggesting the Ad-MSCs basically remained undifferentiated. 
Interestingly, the stemness marker, OCT4, was found upregulated by 3.0~3.5 fold 
(P<0.0001) when the cells were on the fibrous scaffolds. (Fig. 3.2 K)   
3.3.2 Gene expression and protein secretion of paracrine factors by Ad-MSCs 
To investigate the paracrine products of Ad-MSCs and the topological cues that the 
scaffolds may generate, the gene expression and molecular secretion levels were assayed 
through quantitative RT-PCR and ELISA, respectively, on a set of factors that are relevant 




Figure 3.2 A-C, SEM images of the EF scaffolds, REF, AEF and MEF used for cell 
culture. D-F and G-I, SEM and fluorescent confocal images of the Ad-MSCs 
adhered on different EF scaffolds; the boxed areas in F were enlarged in F-1, F-2 
and F-3, showing the morphology of cells adhering to the bundled fibers, cornered 
region and central loose fibers inside the grid on the MEF, respectively. (Scale bars: 
A and B, 5 µm; C and F, 500 µm; D, E, F1-3 and G-I, 50 µm). (G-I, red: cytoskeleton 
stained with rhodamine phalloidin; purple: nuclei stained with DAPI) J, MTS assay 
of the metabolic activities of single Ad-MSC on different substrates. * indicates the 
significant differences between MP and three EF groups on day 1. K, the gene 
expression of MSC differentiation and stemness markers at day 7. All ddCt values 
were normalized to the expression at day 0. (J and K, mean±STD, n=4~6, * P <0.05, 
**P<0.01, ***P<0.001) 
was promoted by varied degrees compared to the control group and the trends found 
in the RT-PCR and ELISA experiments were basically consistent. In particular, 
Cyclooxygenase 2 (COX-2) is an essential enzyme in the synthesis of PGE2, an important 
anti-inflammatory mediator and wound-healing inducer secreted by MSCs.[8, 9, 23] 
Quantitatively, the elevation of COX-2 and PGE2 were the most pronounced among the 
selected factors that were examined: while the COX-2 mRNA levels expressed by the cells 
 
on EFs were about 5.4-, 6.3-, 10.8-fold (P<0.0001) higher on REF, AEF and MEF 
compared to the MP,  respectively, the actual elevation of PGE2 enzymes were ranging 
from 70- to over 300-fold (P=0.007 (MSC-REF), 0.005 (MSC-AEF) and 0.004 (MSC-
MEF))  (Fig. 3.3 A, B). iNOS is another factor whose expression was promoted 
significantly, with the actual secretion increased by 7-,17-and 12-fold on REF, AEF and 
MEF (P=0.005, 0.003 and 0.006), respectively. Among other protein factors, the mRNA 
of the anti-inflammatory TGS-6 was found to increase by around 5-fold (P<0.0001); the 
secretion levels of reparative TGF-β (P=0.028 (MSC-AEF)) and angiogenic VEGF by 
around 3-fold (P=0.006 (MSC-REF), 0.003 (MSC-AEF) and 0.005 (MSC-MEF)). To rule 
out the effects of possible side-products released from scaffolds, the medium conditioned 
by the blank scaffolds was also used to culture MSCs and no influence from the blank 
scaffolds was observed. (Fig. A4) 
When the three different scaffolds were compared, it is noted that the materials 
containing oriented fibers showed more potent effects on promoting the expression of 
PGE2 (P=0.0004 (MSC-AEF) and 0.0125 (MSC-MEF)), iNOS (P=0.0008 (MSC-AEF) 
and 0.0369 (MSC-MEF)), VEGF (P=0.0006 (MSC-MEF)) and HGF (P=0.0016 (MSC-
MEF)) compared to REF, according to the secretion measurements. In effecting the 
production of other molecules, the influences of the three materials were not significantly 
different. To further understand the possible molecular signaling mechanisms involved in 
the elevation of the paracrine secretion by Ad-MSCs, the gene expression of Ad-MSCs 
treated with an NF𝜅B inhibitor, PDTC, was analyzed. NF𝜅B is a key transcriptional 
regulator that is known to mediate cellular responses to external stimuli and the MSC 




Figure 3.3 A, the mRNA analysis of the selected anti-inflammatory and pro-
angiogenic factors expressed by Ad-MSCs. B, the analysis of the paracrine products 
secreted by Ad-MSCs. C, the reversal of the enhanced expression of the anti-
inflammatory and pro-angiogenic factors by Ad-MSCs via the supplementation of 
PDTC, an inhibitor of the NF𝜅B signaling pathway. All values were normalized over 
the microplate (MP) group. (Mean±STD, n=4~6, *P <0.05, **P<0.01, ***P<0.001) 
MSCs, it was shown through the mRNA analysis that the paracrine responses of MSCs 
toward fibrous materials were all significantly reversed (P<0.001). (Fig. 3.3 C) 
3.3.3 In vitro anti-inflammatory and pro-angiogenic function of the Ad-MSC paracrine 
products  
To probe the function of the secretory products of Ad-MSCs, the serum-free media 
conditioned by the Ad-MSCs cultured on different scaffolds and microplates were 
separately collected and applied to the cultures of macrophage and endothelial cells. 
Specifically, the murine RAW 264.7 macrophages were pre-treated with LPS and the 
inflammatory response induced which manifested in the drastically elevated secretion of 
tumor necrosis factor α (TNF-α) and interleukin 1β (IL-1β). When the CM containing the  
 
  
Figure 3.4 The effects of the conditioned medium (CM) derived from Ad-MSC 
cultures on the pro-/anti-inflammatory expression of LPS-stimulated RAW 264.7 
macrophages: A, TNF-α; B, IL-1β; C, IL-10; D: Arg-1. The LPS (+) and LPS (-) 
RAW 264.7 macrophages free of CM treatment were positive and negative controls, 
respectively. All data were normalized over the LPS (+) macrophages treated with 
the MSC-MP CM. (Mean ± STD, n=4~6, *P <0.05, **P<0.01, ***P<0.001)  
secreted products from a normalized number of Ad-MSCs were added, the elevation 
of these inflammatory factors was reversed, including the CM collected from cells on the 
MP. Interestingly, this effect was only most significant from the CM obtained from the 
MSC-MEF system. (Fig. 3.4 A, B) With respect to the beneficial anti-inflammatory factors 
produced by macrophages, IL-10 and Arg-1, they only increased in the groups treated with 
the CM derived from the MSC-AEF and MSC-MEF systems but not MSC-MP and MSC-
REF compared to the LPS (+) group. Among the MSC-EF groups, the effects of the CM 
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collected from the cells cultured on oriented fibers were more potent compared to the MSC-
REF CM, and the MSC-MEF CM showed the most potent effect on promoting the 
expression of IL-10, reaching over 5-fold of the function of the MSC-MP CM. (Fig. 3.4 C, 
D) In the group of MSC-AEF, the upregulated level of IL-10 expression in macrophage 
cells was lower than that of Arg-1. It could be due to other components in the culture which 
enhanced the expression of Arg-1 (such as PGE2/TGF-β/IL-4) or downregulated IL-10 
(such as IFN γ/IL-1β). When the medium conditioned by blank scaffolds was tested on 
macrophages, no effects from the scaffolds were observed. (Fig. 3.4) 
In analyzing the pro-angiogenic function of the CM of Ad-MSCs, the endothelial 
cells treated with or without 1% ECGS were performed as negative and positive controls, 
respectively. It is shown that when the CM samples were applied to the culture, the 
proliferation level of endothelial cells and the total length of the vessel-like tubes formed 
by cells both increased compared to the negative control, suggesting the trophic effects of 
the collected CM. (Fig. 3.5) Among the four groups of CM samples, the effects of the CMs 
collected from the MSC-EF culture were all significantly more potent compared to the 
MSC-MP CM. There is also a trend that the oriented fibers facilitated more production of 
the pro-angiogenic factors from Ad-MSCs in comparison to the random fibers. As is shown 
in Fig. 4, the HUVEC number normalized over the group of the MSC-MP CM was 1.5, 
1.8, 2.0 and the accumulative tube length 1.3, 1.4, 1.5, for the groups treated by the CM 
collected from the MSC-REF, MSC-AEF and MSC-MEF culture, respectively. 
 
  
Figure 3.5 The effects of the conditioned medium (CM) derived from Ad-MSC 
cultures on the HUVECs proliferation (A) and tube formation (B). The blank 
MEM-α supplemented with or without 1% ECGS were used as the positive and 
negative control, respectively. The tube length was calculated by 5 repeated wells of 
96-well plates for each group. All data were normalized over the endothelial cells 
treated with the MSC-MP CM. (Mean±STD, n=4~6, *P <0.05, **P<0.01, 
***P<0.001) C, epresentative images of the endothelial cells forming tubes when 
treated with different CMs. (Scale bar: 200 µm)  
3.3.4 In vivo wound healing effects of the Ad-MSC paracrine products 
To further investigate the function of the paracrine products of the Ad-MSCs and the 
effects of the fiber topography, the CM samples were harvested, concentrated and used for 
treating a skin excisional wound in rats. In these in vivo experiments, the CM from the 
MSC-MEF culture, which showed the optimal effects in the in vitro analysis, was studied 
and compared to the CM samples collected from the MSC-MP culture. In all three groups 
including the negative control of the blank medium, the skin wounds all visually prompted 
healing processes, with the wound closure rate found highest in the group treated by the 
MSC-MEF CM. In particular, the percentage of the healed region reached 76.5 ± 10.7 % 
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(Mean±STD, n=8) at day 7 when the MSC-MEF CM was applied to the skin wounds; in 
contrast, the wound closure was around 38.8% ± 16.3 and 53.3% ± 4.6% in the control and 
the MSC-MP CM groups, respectively. (Fig. 3.6 A, B)  
 
Figure 3.6 The healing effects of the conditioned medium (CM) derived from Ad-
MSC cultures on the rat skin excisional wounds. A, representative photographs of 
the wounds treated by MEM-α or MSC CM at day 4. (Scale bar: 10 mm) B, the 
measurements of the wound closure within 7 days post the CM or MEM-α 
treatment; the table lists the P values for comparing the treatments with MSC-MEF 
CM to those with MSC-MP CM or MEM-α. (Mean±STD, n=8, one-way ANOVA) C, 
the micrographs of the H&E- and Masson’s trichrome (MT)-stained wounds at day 
14. The arrows in the MEF-MSC CM group in bottom left and bottom middle 
images indicate appendage-like structures. (Scale bars: images in the left (H&E) and 
middle (MT) columns, 200 µm; images in the right (MT-amplified) column, 50 µm)  
In the histological analysis, it is shown through H&E-staining that full 
epithelialization were attained in the excisional regions in all three groups (Fig. 3.6C) at 
day 14. The Masson’s trichrome staining revealed the dermal layer in the group of MSC-
MEF CM contained collagen deposition in a fine reticular pattern, in resemblance with the  
 
  
Figure 3.7 A, Fluorescence confocal microscopic analysis of the wound sections 
stained with the microphage pan-maker, CD68 (red), the M2 phenotype marker, 
CD206 (green), and nucleus marker, DAPI (blue). (yellow: co-staining of CD68 and 
CD206 markers) B, the percent population of CD 68+ macrophages over the total 
number of cells. C, the percent CD206+CD68+ cells over the CD 68+ cells in the 
wound bed under MEM-α, MSC-MP CM or MSC-MEF CM treatment at day 7. 
(Mean±STD, n=20; scale bars: 200 µm)                                                                                
normal dermal tissue. Moreover, appendage-like structures were also visible. In contrast, 
the collagen in the MEM-α and microplate CM groups appeared to be haphazardly 
arranged and thick, showing the traits of fibrotic deposition. (Fig. 3.6 C) 
In wound healing, macrophage cells play a key role in intercellular communications 
to modulate the inflammatory and reparative processes. The tissue slides of the wound beds 
at day 7 were immunostained for CD68 and CD 206, a pan-macrophage and a M2 
macrophage maker, respectively, to probe the macrophage phenotype. As is shown in Fig 
6, in all three groups, macrophage cells and M2 macrophages were stained positively to 
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various degrees. In particular, the density of the macrophage cells (Fig. 3.7A) in the wound 
beds were highest in the MSC-MEF CM group: The percentages of the CD68+ 
macrophages over the total cells and the dually stained CD206+CD68+ cells over the total 
CD68+ cells were about 34.0% and 57.8%, respectively.   
                                                                                                                                                                         
3.4   Discussion 
The combinatorial use of cells and materials has become an important approach in cell-
based therapies, in which understanding the interaction between cells and materials and the 
associated mechanisms is essential to developing functional materials for future 
regenerative medicine. It is desirable that biomaterials could be generated to provide 
microenvironment for controlling different cell behavior. The influence of materials on 
cells, however, is intricate, and much is unknown on how cells should be manipulated to 
achieve the optimal cell function and thereby therapeutic outcome in vivo. In the settings 
where the stem cells need to replenish the cell loss caused by injury, the function of 
materials to enhance cell differentiation and prolong the residence time is key and has been 
intensively investigated. Evidences obtained through many years of in vivo studies, 
however, have shown that the transplanted cells would only exist for a relatively short 
period of time in the host due to the complex host reactions, and the paracrine activity of 
cells may provide a new effective approach in mediating molecular network within the 
environment towards tissue regeneration.   
In fact, animal studies have shown that the paracrine signals produced by MSCs were able 
to evoke responses from local cells in the tissue to initiate regeneration [72, 87], and the 
 
paracrine process might also be responsible for the therapeutic effects of MSCs in clinical 
trials in treating heart ischemia, skin wounds and bone/cartilage injuries.[20, 88-90] On the 
other hand, it is noticed that in the practices involving the injection of MSCs, the cells 
usually need to be activated/stimulated [91] through pro-inflammatory factors (e.g. TNF-
α, LPS and toll-like receptor (TLR) ligands) or hypoxia condition (i.e. reduced oxygen 
concentration or 3D spheroid culture). The rational is based on the fact that MSCs can 
respond to inflammation or hypoxia through producing elevated levels of modulatory 
paracrine factors including pro-angiogenesis or anti-inflammatory cytokines. [23, 91-93] 
Recently, a few studies showed that nanoparticles conjugated with extracellular matrix-
derived peptide, collagen or hyaluronic porous scaffolds had the potency to promote MSCs 
paracrine function in vitro.[83, 94-97] However, there was no direct in vivo study that 
investigated the therapeutic effects of the paracrine products derived from MSCs cultured 
on biomaterials. Also, little is known regarding how fibrous scaffolds, especially the 
topologic characteristics, would affect MSCs paracrine function.  
Through profiling the important cytokines that are relevant to the pro-angiogenic and anti-
inflammatory function of MSCs, our study unambiguously indicates that the fibrous 
topography provided unique microenvironment that could enhance the paracrine secretion 
of Ad-MSCs. The in vitro functional assay of the conditioned-media was correlated with 
the quantitative analysis of the cytokines. The Ad-MSCs anti-inflammatory cytokine 
secretion on scaffolds was capable of promoting macrophages to demonstrate M2-like 
phenotype in vivo (Fig.6A, 6C). Similarly, the effect of the CM on the tube formation and 
endothelial proliferation may be related to the TGF-β, bFGF and VEGF factors observed 
in the cytokine assay. Compared to other methodologies, the upregulation of PGE2 
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secretion level which was 233.9±56.3 fold of the  MSC-MP group in our study could be 
significantly higher than the systems involving inflammatory stimuli and 3D culture in the 
literatures.[73] [95, 98] Another interesting aspect is that the secretion of anti-inflammatory 
and pro-angiogenic factors were both upregulated by the fibrous scaffolds, whereas the 
results in favor of only one category of factors were reported. For example, the MSCs 
cultured on porous scaffolds showed a lowered level of VEGF secretion despite the 
elevation in the production of  PGE2 [98]; the hypoxia condition could only induce 
angiogenic molecule secretion but not any anti-inflammatory molecule secretion.[99]  
Our study showed that the mechanism associated with the topographical effects of 
scaffolds on MSCs could share a similar down streaming signaling molecules, NF𝜅B, with 
other methodologies. NF𝜅B signaling pathway but not the JNK-dependent mechanism, has 
been indicated in the stimulation of MSCs through TNF-α, hypoxia and LPS; it is also a 
rapid acting factor to regulate of the expression of many genes involved in inflammatory 
processes. [100, 101]  It is therefore reasonable to speculate that the fibrous scaffolds might 
trigger cellular responses similar to an external inflammatory stimulus. In Fig. 1J, it was 
observed that the metabolic activity of MSCs was much higher on the EF scaffolds in the 
first few days and reduced to levels close to the cells on the microplates. The result might 
be indicative of the dynamic effects of the scaffolds on cells: Upon the contact with fibers, 
cells responded through adhesion and cytoskeletal reorganization, and the enhanced 
activity diminished with time. As seen in Fig. 1K, the Oct4 gene in MSCs was upregulated 
under the influence of the EF scaffolds. The observation suggests that the fibrous 
topography may also be beneficial for maintaining the stemness of MSCs as well as the 
relevant cytokine repertoire, as the cells were not committed to a specific cell/tissue type. 
 
More advanced methodologies need to be established to capture the compositional and 
kinetical characteristics of cytokine release from cells to obtain in-depth understanding of 
the cell-scaffold interactions.  
In our study, it was shown that the fibrous topography not only exhibited the effects on 
enhancing the paracrine function of MSCs, the cells also exhibited differential responses 
on three types of scaffolds containing fibers of different orientation characteristics. Among 
the cytokines examined, the oriented fibers seemed to enhance the expression of PGE2, 
iNOS and HGF. In the functional assay, the CM derived from the MSC-MEF culture 
showed potent effects on promoting the anti-inflammatory responses of macrophage cells, 
showing significant differences compared to the random fibers. On the other hand, the anti-
inflammatory function of CM of the MSC-MEF culture was also more significant 
compared to its pro-angiogenesis function in the assay of endothelial cells. The underlying 
mechanisms responsible for the function of MEF need to be further understood, given the 
complicated microenvironment on the MEF scaffold, which induced cell shapes between 
the round cell shape on REF and the fully stretched cell on AEF.  Our results are also 
comparable to previous studies which showed that the Ad-MSC phenotype, e.g. 
multipotency and osteogenenic/adipogenic differentiation, may be alterable by substrates 
affecting cell orientation and shape.[76, 79]  
Studying the paracrine function of cells has profound implication for understanding how 
the cells transplanted in vivo can facilitate the tissue repair/regeneration processes [89, 
102], which thereby can shed light on the design principle for scaffold materials. Once 
transplanted, the exogenous cells may be exposed to a myriad of molecules and cells 
generating signals to mount reactions that determine the fate of the graft. [103] The cells 
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may also suffer from hypoxia condition if transplanted at an extra-vascular site with 
insufficient blood supply.[104, 105] A third complexity may come from the pathological 
environment involved acute or chronic inflammatory factors in injury. [106] These 
complex conditions can lead to minimal or transient therapeutic effects of transplanted cells. 
By applying the CM to the skin wound, it is clearly shown that the repertoire of Ad-MSCs 
paracrine products derived from the MSC-MEF system did contain therapeutic substances 
that may benefit tissue regeneration. This result matches the in vitro functional assays in 
which the pro-angiogenic and anti-inflammatory potency of the conditioned media were 
observed. Based on our study, the paracrine products of Ad-MSC may have played roles 
in promoting the skin repair/regeneration through the various pro-angiogenic and anti-
inflammatory factors.  
One mechanism might be linked to the ability of the CM to modulate the activities of 
macrophages (Figure 6A, C) in the wound bed toward the resolution of inflammation and 
repair of tissues.[107, 108] It is known that the wound in the skin of vertebrates can contain 
the pro-inflammatory macrophages which through cytokine signals (e.g. TNF-α and IL-
1β ) instruct fibroblasts to produce unorganized collagen, leading to the formation of scar 
tissue and inadequate regeneration of dermal appendages. [109, 110] It is possible that in 
our study the MSC-derived PGE2, which was shown increased significantly in vitro, 
promoted the secretion of IL-10 in macrophages and reduced the secretion of TNF-α and 
IL-1β, through the activation of the EP4 receptor on macrophages.[23] Also, the TSG-6 
secreted by Ad-MSCs, may also attenuate inflammation by decreasing TLR2/NF-𝜅B 
signaling in resident macrophages.[111] Other beneficial effects of modulating cell-cell 
communication network through macrophages might include promoting the activity of  
 
 
Figure 3.8 Schematic of the MSCs under the influence of scaffolds to generate 
paracrine products to modulate the cell communication network toward tissue 
repair/regeneration.  
progenitors in the skin wounds, as shown in the studies which suggested the role of 
macrophages in the differentiation of myoblasts and oligodendrocyte progenitor cells in 
respective regeneration of smooth muscle and in central nervous tissue.[112]  
A summary of the involvement of the scaffold-MSC construct in the cellular 
communications is depicted in Fig. 7. More studies will be needed to further elucidate 
relationships in the interplay of scaffolds, transplanted cells and host tissue so that the 
beneficial effects of the paracrine factors can be controlled and maximized. In particular, 
extracellular vesicles (EVs) are membrane-surrounded structures released by cells and play 
important roles in the intercellular transmission of biological signals to regulate 
immunomodulatory and tissue repair processes. Recent studies have shown that the EVs 
released by MSCs, including microvesicles and exosomes, have therapeutic effects on 
tissue injuries, which could be attributed to the protein and microRNA cargoes contained 
in EVs.[113-116] It was possible that the cytokines examined in this study was also 
relevant to the EV structures. It will be of great interest to further explore the release of 
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EVs on scaffolds to gain a mechanistic understanding of how materials may be used to 
potentiate the function of MSCs. 
Lastly, as shown in our study, MSC-derived conditioned medium may be directly 
developed into therapeutics as regenerative medicine.[117] Compared to cell 
infusion/transplantation, harvesting secreted products from cells would avoid introducing 
live cells into the body, and allow for more convenient control of the dosage and storage 
of the therapeutic substance. The studies on the use of CM of MSCs for treating various 
diseases increased rapidly in recent years [117-119], including the development Ad-MSC 
CM for hair follicle regeneration [120] and wound healing in human [121]. On the other 
hand, it is a great challenge to establish the regulatory policies to address the quality, safety 
and efficacy of this new category of therapeutics containing mixed components. As 
mentioned above, isolating the EVs in the CM  is a promising direction; however, the 
markers and components of EVs should be profiled and the reproducibility and consistency 
of the products be established to ensure the quality.[122-124] With the regulatory 
consensus, the design of the in vitro culture condition and exploration of the function of 
fibrous scaffolds would then provide approaches to improve the therapeutic efficacy of 
CM-derived products.   
  
 
CHAPTER 4.   DESIGN OF EXOSOME-LOADED SCAFFOLDS 
FOR REGENERATIVE IMMUNOMODULATION 
The immune system has been identified as a key mediator in tissue regeneration by 
playing critical roles in angiogenesis, fibrosis and tissue remodeling. Implantation of 
designer scaffold materials can involve both innate and adaptive immunity which could 
potentially be manipulated to generate pro-regenerative tissue responses. Mesenchymal 
stromal cells (MSCs) provide promising repair/regenerative modalities in many diseases 
through their paracrine products, and the exosomal secretion by MSCs in particular exhibits 
the immunomodulatory properties by targeting a broad spectrum of immune cells. Here, 
we developed a method to create electrospun fibrous scaffolds bound with MSC exosomes 
and investigated the immunomodulatory function of the new biological materials as cell-
free constructs for tissue regeneration. The fibrous scaffolds were fabricated with 
morphological features to attract immune cells and the MSC exosomes were utilized to 
further educate the recruited cells towards pro-regenerative immune reactions. The results 
showed that exosomes were efficiently loaded onto the poly(ethylamine)-modified 
electrospun fibers and the electrostatic binding between exosomes and the scaffold allowed 
the uptake of exosomes by macrophages which were induced with M2-like phenotypes in 
vitro. In the immunological analyses post-implantation, local M2-biased responses at the 
implantation site and remote Th2 immune responses and increased population of regulatory 
T cells in the lymphatic tissue or spleen were observed in a wound healing model. The 
results suggested the immunomodulatory function of MSC exosome-loaded scaffolds and 
 
 85 
the design of functional synergy between exosomes and materials presented a new 
paradigm to promote tissue regeneration. 
4.1   Introduction 
Immune systems are best known for the role of first line against pathogens. They 
were also responsible for tissue development, homeostasis, and tissue repair/regeneration. 
Varieties of immune cell types are proved to be involved in the process of tissue repair.[112] 
Through their behavior of phagocytosis, timing of present and retreat, shifting of cytokine 
secretion, the immune cells construct an integrated environment to impact the key events 
of tissue repair/regeneration, including stem/progenitor cell proliferation/differentiation, 
angiogenesis, tissue remodeling.[125-128] Macrophages are most well studied immune 
cells that could mediate different stages of tissue repair post injury due to their highly 
programing possibilities.[3, 129] The pro-inflammatory M1 macrophage are responsible 
for debris clearance, but long-lasting M1 response will lead to chronic inflammation and 
impair healing. Macrophage shift towards reparative M2 macrophage has been identified 
as a signature event presenting a benign tissue repair in heart, muscle, neuron etc. post 
injury.[1, 130-132] Recent studies showed the adaptive immune cells also participates in 
tissue repair, especially the T cells.[133] Regulatory T cells (Tregs) are able to secreting 
immunomodulatory cytokines, such as IL-10 and TGF-β, that skew macrophage towards 
M2 phenotype as well as growth factors, such as amphiregulin, that directly induce the 
proliferation and differentiation of tissue resident progenitor cells thus favor tissue 
regeneration.[8, 11, 14] CD4+ T helper 2 (Th2) secrete IL4 and IL10 to cross talking with 
innate immune cells such as macrophage and favor tissue repair.[16, 17] Whereas CD8+ T 
 
cells and CD4+ T helper cells are considered to promote inflammation and negatively 
influence reparative process.[18] 
Mesenchymal stromal cells (MSCs) is the most widely-used stem cell type in clinical 
applications aimed at tissue repair and immunomodulation, achieved by their strong 
secretion capacities.[134] Due to the versertile bio-functional components harbored in the 
MSC secretome, MSCs have the ability to target and modulate the behavior of many 
immune cell types, such as convert macrophage towards M2 phenotype, inhibit DC 
maturation, suppress differentiation of B cells and effector T cells, increase Treg 
population, induce Th2 immune response and suppress NK cell activity etc.[135, 136] 
Exosomes are membrane-surrounded nano-vesicles released from MSCs shuttling cargos 
of proteins and RNA as important intercellular messenger, assembling similar 
immunomodulation properties of MSCs.[137-142] MSC exosomes have been used as 
substitute of live cells and showed equivalent immunomodulatory functions and 
therapeutic effects as cell transplantation in many tissues.[113, 116, 143] Moreover, 
exosomes relieve the safety risk brought by live cell transplantation, meanwhile could be 
easily stored and transported. Therefore, MSCs exosomes are potent candidate for 
regenerative immunomodulatory material design. 
With the knowledge how the immune system greatly influences the process of tissue 
repair/regeneration, tuning immune system towards pro-regenerative state based on the 
criteria of immune response for specific tissue to heal properly is a new realm for 
regenerative medicine. Many studies have tried to manipulate the behavior of macrophage 
by utilizing the physicochemical properties of the biomaterials or using biomaterials as a 
delivery tool for immune modulators. As the adaptive immune response, especially the T 
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cells, were identified as key participants in tissue regeneration other than innate immune 
cells, immunoactive biomaterial design to crosstalk with broader spectrum of immune cells 
and generate new pro-regenerative immune events are of great promises that has hardly 
been explored. Recently, the extracellular matrix (ECM) bio-scaffolds were shown to drive 
reparative microenvironment in the traumatic tissue injury and this process is dispensable 
of T helper 2 cells participation. This study has exhibited the power of nature-derived 
biomaterials to generate adaptive immune response for promoting tissue regeneration.[144] 
Therefore, to further design the immunomodulatory biomaterials, especially synthetic 
materials, and explore their role in both innate and adaptive immune response in vivo for 
tissue regeneration is of great interest and importance. 
Electrospinning has the advantages of the convenient fabrication process, the wide 
choice of materials and the precision control over fiber parameters and architectures, thus 
provide an easy and quick tool box for regenerative immunomodulatory material design. 
The architectural and topographical cues of scaffolds influence immune cell activities, such 
as adhesion, proliferation, or secretion profiles. In particular, the fiber orientation, diameter 
of EFs and the pore size of the EF membranes have been found to regulate macrophage 
recruitment and phenotype commitment differently. [145, 146]  Physiochemical properties, 
such as surface charge and hydrophilicity or bio-functional molecule introduced by blend 
electrospinning or surface modification are also modalities of EFs to modulate immune 
system both in vitro and in vivo. Moreover, EF scaffolds have the structure assembling the 
natural ECM and have been assessed as useful platforms for designing functional wound-
dressing materials. However, the studies mainly focused on EF scaffolds as a delivery tool 
and substrate for cell infiltration but neglect their intrinsic immunomodulatory properties 
 
when aiding wound healing.[147-150] Indeed, the immune response towards implanted EF 
scaffolds are inevitable and the involved subsets of immune cells can thus be targeted and 
manipulated for immune-mediated tissue regeneration through materials design. 
Here we developed a MSC exosome loaded EF scaffolds for regenerative 
immunomodulation in the wound healing model. We hypothesized that the EF scaffolds 
would recruit immune cells to the transplant site due to foreign body reaction in vivo; the 
recruited immune cells will then receive the immunomodulatory signals from the MSC 
exosomes and generate immune environment that favor the tissue repair/regeneration. 
Through series of chemical modification, micro- polycaprolactone (PCL) EFs were 
covalently conjugated with polyethylenimine (PEI) to passively load exosomes through 
static interaction. The exosome loaded PEF (Exo-PEF) were then applied to a wound 
healing model in vivo and the immunomodulatory properties of the innate and adaptive 
immune response were evaluated in both local sites and remote lymphatic organs. Our 
study suggests the designed exosome loaded EF biomaterial system have active 
immunomodulatory properties in vivo and resulted in adequate immune cell subtypes with 
phenotype that have been identified as positive role in immune-mediated regeneration. By 
exploring the adaptive immune response in the lymphatic organs, this study also brings 
new angles, that worth considering for regenerative immunomodulatory material design in 
the future. 
4.2   Materials and Methods  
4.2.1 Materials and reagents 
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Ultrapure water ≥18 MΩ was derived from deionized water though a Milli-Q 
system (Millipore, Billerica, MA). Polycaprolactone (PCL) and lipopolysaccharide (LPS) 
were obtained from Sigma-Aldrich (Milwaukee, WI). TRIzol kit, Dulbecco’s phosphate 
buffered saline (DPBS), PRMI mdium, DMDM medium and other cell culture reagents 
were purchased from Invitrogen (Carlsbad, CA, USA) unless otherwise specified. 4',6-
diamidino-2-phenylindole (DAPI) and Rhodamine Phalloidin was obtained from the 
ThermoFisher (MA, USA). Human umbilical vein endothelial cells (HUVECs), 
Endothelial cell medium (ECM), endothelial cell growth supplement (ECGS) and were 
purchased from ScienCell (Carlsbad, CA). Mice bone marrow mesenchymal stromal cells 
(BM-MSCs) and it’s culture medium basal medium were purchased from Cyagen 
Biosciences Inc (Santa Clara, CA, USA). The murine-macrophage cell line RAW 264.7 
were obtained from the Cell Culture Center of the Institute of Basic Medical Sciences 
(Beijing, China). Tumor necrosis factor-alpha (TNF-α), macrophage colony-stimulating 
factors (M-CSF), interleukin 4 (IL4) were purchased from Peprotech. (Canada) Suppliers 
of other chemicals, biological reagents, and equipment are specified below. The flow 
cytometry antibodies and reagents were purchased from Biolegend (US) uless otherwise 
specified. 
4.2.2 Cell culture 
All cells were cultured at 37°C under humidified atmosphere with 5% CO2. The BM-
MSCs were cultured in basal medium supplemented with 10% fetal bovine serum (FBS), 
0.4% penicillin/streptomycin (P/S). The BM-MSCs between passage 5 and 9 were used for 
the following experiments. The human umbilical vein endothelial cells (HUVECs) were 
 
maintained in endothelial cell medium (ECM) supplemented with 5% FBS, 1% (P/S) 
solution and 1% ECGS. RAW264.7 macrophages (MΦ) were cultured in DMEM 
supplemented with 10% FBS and 1% P/S. Macrophage isolated from bone marrow of 
Balb/c mice were cultured in PRMI supplemented with 0.25mM beta-mercaptoethanol, 1 
× non-essential amino acid, 10% heat inactive FBS (FBS incubated at 56℃ in water bath 
for 30mins), 1% penicillin & streptomycin and 20ng/mL G-CSF. To detach cells from the 
culture plates, BM-MSCs and HUVECs were treated with trypsin/EDTA solutions, while 
macrophages were pipetted repeatedly to induce the detachment. 
4.2.3 Isolation and identification of BM-MSC exosome 
BM-MSCs at 80% confluent in cell culture flask were cultured in serum-free medium 
for 24 hours to collect the supernatant. The supernatant was centrifuged at 1,200 g for 15 
min, followed by 10,000 g for 30min to remove cell debris and apoptotic bodies. The 
exosomes were precipitated by ultra-centrifuged at 100,000 g for 1h, and was washed twice 
with PBS. The precipitated exosomes were resuspend in 200 µL PBS, stored in -80 °C until 
use. The protein content of collected exosomes was measured by micro BCA protein assay 
kit (Thermo Fisher). The collected exosomes were fixed with 4% paraformaldehyde (PFA), 
stained with 2% (w/v) uranyl acetate for 5 mins, washed 3 times with DI water and the 
exosomes morphologies were observed by transmission electron microscopy. (Tecnai G2 
T20) The size and zeta potential distribution of exosomes were identified by Zetasizer 
(Brookhaven Instruments). To identify exosomes, 10 µg exosomes were covalently 
conjugated onto 4-µm aldehyde/sulphate latex beads for 15min. The excess aldehyde group 
were blocked by excessive 100 mM glycine for 30 min. The exosome-beads were stained 
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by exosomal markers CD63/CD9 and according isotypes and analyzed by BD Aria flow 
cytometer. For mass spectrum, exosomes were lysed in lysing buffer (6% SDS, 200 mM 
DTT, 200 mM Tris-HCl, pH 7.6.) at 95°C for 5 min followed by filter aided sample 
preparation (FASP). 
4.2.4 Fabrication and characterization of BM-MSC exosome-loaded PEI modified 
electrospun fibrous (Exo-PEF) scaffolds 
Electrospun fibrous (EF) scaffolds were prepared from polycaprolactone (PCL) 
solution. 21% w/v PCL was dissolved in a mixture of CHCl3 and dimethylformamide at 
the volume ratio of 9:1. After stirring for 3 h until PCL was completely dissolved, the 
solution was loaded into a syringe with a blunt-ended stainless 21G steel needle. The 
feeding rate and the applied voltage were controlled at 2 mL/h, 10kV, respectively. The EF 
was collected on a flat steel plate covered with foil paper at a distance of 14cm from the 
needle tip. Sodium hydroxide treatment was employed to enhance the PCL EF 
hydrophilicity and induce carboxyl group to the EF for further modification of 
poly(ethylamine) (PEI). PCL EF scaffolds were immersed in the mixture of 1M aqueous 
sodium hydroxide solution and 75% ethanol solution (v/v) at the ratio of 1:1 for 30mins 
with gentle agitation at room temperature. After hydrolysis, the scaffolds were washed with 
large volume of DI water.  
To covalently modify PEI to the EF, sodium hydroxide treated PCL EF was rinsed 
in 0.1M 2-Morpholinoethanesulfonic acid (MES) buffer, pH 5.1. 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC) (Pierce Biotechnology Inc.) and 
water soluble sulfo N-hydroxysuccinimide (Sulfo NHS) (Pierce Biotechnology Inc.) were 
 
dissolved in ice cold 0.1M MES buffer and added dropwise to the EF. EDC activation was 
done for 2h on the shaker at room temperature. 70 kDa branched PEI (Macklin, Shanghai, 
China) was diluted in 0.2 M MES buffer, pH 6.5. Activated PCL EF were transferred to 
the PEI solution incubated for another 2h at room temperature on an up-down rotator. PEI-
conjugated EF (PEF) were washed 4 times in excess 1 M NaCl to remove physically 
adsorbed PEI. To confirm the success of PEI conjugation, 2,4,6-Trinitrobenzene sulfonic 
acid (sigma) (TNBSA) assay were performed to detect the existence of amine group on the 
surface PEF by forming of a highly chromogenic (orange) product. The TNBSA assay were 
also performed in the solution that rinsed PEF overnight to confirm fully removal of 
unbound PEI. 
The water contact angles of the PCL EF scaffolds before and after PEI modification 
were measured at room temperature and 60% relative humidity, using sessile drop method 
on a contact angle analyzer (USA Kino Industry Co., Ltd). For sterilization, EF membranes 
were rinsed with 75% ethanol solution for 30 mins and then washed with sterilized DI 
water for three times and air dried in bio-safety cabinet (Thermo, Germany). The EF 
scaffolds were exposed under ultraviolet radiation for 30 min on each side in the bio-safety 
cabinet for further sterilization and were kept in sterile dishes at 4°C until being used. Up 
to 30 µg BM-MSC exosomes were dissolved in 1mL PBS, added to manually tailored 
12mm diameter PEF, rotating for 30 min at 4°C. The loading capacity of PEF were 
determined by protein content remained in the PBS after exosome loading. The loaded 
exosomes were determined by the difference between the protein content before and after 
loading. The morphology of EF in each step was characterized by scanning electron 
microscopy (SEM) (Quanta FEG450, FEI, US). 
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4.2.5 HUVEC proliferation assay 
To determine the change of cell adhesion properties of EF after series of chemical 
and biological modification, HUVECs were seeded on PCL EF, NaOH treated PCL, PEF 
and Exo-EF (10 µg), with HUVEC cultured in microplates supplemented with or without 
exosomes (10 µg) as a control. After 24 h, cells were fixed in 2% PFA and stained with 0.5 
µg/mL DAPI for 10 min. Fluorescence images fully covering the microwell/EF were 
captured by an IX71 fluorescence microscope (Olympus), and the number of cells in each 
well was counted by ImageJ software.  
4.2.6 Trans-well system 
The exosomes were incubated with 0.1mM DiI, washed with PBS for three times to 
remove excessive dye. A trans-well microplate with pore size of 0.4 µm that allow 
substance transfer but avoid cell-material contact between upper and lower chambers was 
used. The exosomes/Exo-EF were placed on the upper chamber and 2×105 macrophage 
RAW264.7 was seeded in the plate in the lower chamber. Exosomes that directly added to 
the macrophage or macrophage seeded on the Exo-EF membrane were used as a control.  
4.2.7 Macrophage gene and secretion profile 
Bone marrow cells from femurs and tibias from mice were harvested and cultured in 
RPMI medium, supplemented with 0.25mM beta-mercaptoethanol, 1 ×  non-essential 
amino acid, 10% heat inactive FBS (FBS incubated at 56℃ in water bath for 30mins), 1% 
penicillin & streptomycin and 20ng/mL G-CSF. Medium was changed every other day. On 
day 7, the bone marrow-derived macrophage (BMDM) was stained by F4/80 antibody and 
 
analyzed by flow cytometry to determine the differentiation of BMDM. BMDM were then 
detached and seeded onto PCL EF, PEF and Exo-EF (10 µg exosomes) or 48-well 
microplate supplemented with or without 10 µg exosomes at the density of 2×105 per 
scaffold/microwell. BMDM were classically activated with LPS (100 ng/ml, Sigma-
Aldrich L2880).  Supernatant was harvested at 24 hours post-seeding, TNFα and IL10 were 
in the supernatants were determined by ELISA assay. Cells were treated with TRIzol kit 
and total RNA was extracted, reverse transcribed with TransScript First-Strand cDNA 
Synthesis SuperMix (Transgene, Beijing, China) The gene expression levels were analyzed 
using the SYBR Green real-time PCR method and quantified using the Bio-Rad CFX 
connect real time PCR system (Bio-Rad, Hercules, CA). Primers were ordered from 
Sangon (Shanghai, China). The sequences of primers for qRT-PCR were listed in Table 1 
in the supplementary information (Supplementary Table 1). All gene expression values in 
one sample were normalized to the beta-actin level. Relative expression was calculated 
using the comparative Ct method. The mean minimal cycle threshold values were 
calculated from triplicate reactions.  
4.2.8 In vivo imaging of exosomes 
The exosomes were incubated with 10 nM DiI, washed with PBS to remove 
excessive dye. The DiI labeled exosomes were either directly injected or loaded onto PEF 
and implanted to the abdomen of mice subcutaneously. The biodistribution of exosomes in 
live mice under isoflurane anesthesia, was determined using an IVIS 200 Optical Imaging 
System (Xenogen, Caliper Life Sciences). All mice were imaged with identical instrument 
settings with excitation wavelength at nm, emission wave length at nm. 
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4.2.9 Mice wound excisional model 
All procedures were performed in accordance with the regulations approved by the 
Institutional Animal Care and Use Committee (IACUC) of Peking University. Balb/c 
female mice (Vitalriver, Beijing, PR China) weighing at 10-week old were anesthetized; 
two 8-mm diameter round full-thickness excisional skin wounds were created using a 
biopsy puncher following the hair removal from the dorsal skin. The PCL EF, PEF and 
Exo-EF (30 µg exosomes) with 12mm diameter were implanted subcutaneously at the 
injury site. For exosome group and PBS wound control group, 200uL exosomes (30 µg) in 
PBS or blank PBS were injected subcutaneously around the wound. Finally, a Tegaderm 
(3M, MN, USA) was placed over the wounds to keep the wounds clean and avoid 
contamination. Digital photographs of the wounds were taken at day 0, 3, 7, and the wound 
area measured by the ImageJ software. The percentage of the wound closure was calculated 
as: (area of original wound - area of actual wound) / area of original wound × 100%. 
4.2.10 Histology and immunostaining 
Mice were sacrificed at day 7 or day 14. The skin tissues including the wound and 
the surrounding skin were harvested and was cut into two parts from the middle line for 
histology observation. The dermal specimens were then fixed with 4% PFA, embedded in 
paraffin and cut into sections with thickness of 5 µm. The sections were stained with 
hematoxylin and eosin (H&E) or Masson’s trichrome (MT), imaged using a light 
microscope (Olympus, Japan).  
4.2.11 Immunomodulation assay of Exo-PEF in vivo  
 
For immunomodulatory properties of Exo-PEF in vivo, The PCL EF, PEF and Exo-
EF (30 µg exosomes) with 12mm diameter were first implanted to the naïve mice. A 
scission and a pocket was made, and materials were subcutaneously implanted at the 
abdomen of the naïve mice. Exosomes (30 µg) and PBS were injected subcutaneously as 
control groups. Scission and pocket were in all mice. At day 14, mice were sacrificed, 
inguinal lymph nodes, spleen and implant sites were harvest. To get single cell suspension 
for flow cytometry assay, lymph nodes were minced and flushed with PBS (with 2% FBS) 
with a 70 µm filter beneath; spleen were cut into pieces, digested in collagenase D (2mg/mL, 
Roche) for 30 min, minced and flushed with PBS (with 2% FBS) with a 70 µm filter 
beneath, followed by RBS lysis treatment (Biolegend); implant sites were scraped to 
remove fat tissue, cut into pieces and incubated in digesting buffer (100ug/mL Liberase 
TM (Roche), 1mg/mL collagenase D (Roche), 1mg/mL hyaluronidase (Sigma) in 
OptiMEM (invitrogen)) for 1.5h at 37 °C on a shaker, minced and flushed with PBS (with 
2% FBS) with a 70 µm filter beneath. 
To explore the immunomodulatory function of Exo-PEF in a disease model, wounds 
were created and materials were implanted as mentioned above. The skin of healthy mice 
and wounds injected with PBS were used as controls, designated as HC and WC, 
respectively. Mice were sacrificed and the wound sites, LN and spleen were harvested at 
Day3, 7 and 14. Single cell suspension were prepared as described above. 
For flow cytometry staining, samples first went through FC blocking with anti-mouse 
CD16/32 for 5mins, then stained with fluorescent antibodies CD3, CD4, CD11c, CD25, 
F4/80, CD86. After fixation, samples were treated with intracellular staining 
permeabilization wash buffer, stained intracellularly for Foxp3, CD206. For intracellularly 
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staining of cytokines IL4, IFN-γ, IL10, TNF-α, samples were incubated with Brefeldin A 
for 4 h before all staining steps. 
4.2.12 Statistical analysis 
Quantitative results were presented as means±standard deviation (SD). Statistical 
comparisons were performed by one-way analysis of variance (ANOVA) followed by 
Holm-Sidak tests to compare selected data pairs. Values of P < 0.05 were considered 
statistically significant. 
4.3   Results  
4.3.1 Preparation of exosome loaded electrospun fiber scaffolds 
MSCs exosomes were visualized by TEM and the classic “cup-shaped” morphology 
were observed. (Fig. 4.2 A). The zeta potential and size of the exosomes were measured 
by DLS. The result showed MSC exosomes we collected has a diameter varied from 50 
nm to 100nm approximately. The zeta potential of exosomes was around negative 30mV 
(Fig. 4.2 B), witch allowed the further coupling of exosomes to the PEF through static 
interaction. The unmodified EF (UEF) were modified with PEI for two purpose: first is to 
improve the hydrophilicity of the EF for better cell attachment; second is to introduce 
positive charge for coupling of exosomes. Newly synthesized PEF were rinsed in the PBS 
upto 48 hour and no amine groups could be detected in the rinsed PBS by TNBSA assay, 
which proved the excessive PEI were thoroughly removed. (Supplementary Fig. 2A) 
 
 
Figure 4.1 Unmodified PCL electrospun fiber (UEF) were first treated with NaOH 
to generate carboxyl group on the EF surface. The PEI were then covalently 
conjugated to the EF through reaction between carboxyl group and amine group, 
designated as PEF. Exosomes isolated from MSCs supernatants were then loaded to 
the PEF through static interaction, designated as Exo-PEF. The Exo-PEF were 
transplanted to either healthy mice or in wound healing model of mice to study the 
regenerative immunomodulation in transplant site/wound site, spleen, and inguinal 
lymph nodes (LN) driven by Exo-PEF. The UEF and injection of exosomes and PBS 
were served as controls. 
On contrary, the PEF showed the color reaction in TNBSA assay (data not shown), 
indicating the conjugation of PEI to the EF. The UEF and PEF morphology and diameter 
were shown in figure 4.3 A, and no significant change in EF morphology were observed 
before and after PEI modification. However, the hydrophilicity of the EF was significantly 
improved by modification of PEI. (Fig. 4.3 B) The PEF could load up-to 30 µg exosomes 
in terms of protein content per cm2, significantly higher compared to the maximal exosome 
loading capacity of UEF, which is around 0.5 µg per cm2. (Fig. 4.3 D) When rinsing Exo-
PEF in the PBS, the loaded exosomes were not released up-to 72 hours determined by 




Figure 4.2 A, SEM imaging of BM-MSC exosomes. Scale bar indicates 50 nm. B, 
Size and zeta potential of BM-MSC exosomes 
fluorescence DiI could be visualized by the confocal imaging, showing exosomes were 
distributed along the electrospun fibers. (Fig. 4.3 C) The SEM imaging also showed 
roughness change of the fiber (Fig. 4.3 C) surface compared with UEF and PEF shown in 
figure 4.3 A. To confirm the series of modification to EF had improved the surface 
properties for better cell engraftment, human umbilical vascular endothelial cells (HUVEC) 
were seeded on the EF and showed improvement cell proliferation on Exo-PEF compared 
to UEF. (Supplementary figure 5) 
 
Figure 4.3 A, the SEM morphology of UEF, PEF and the fiber diameter distribution 
of PEF. Scale bar indicates 2µm. B, Water contact angle of UEF and PEF. C, 
Confocal imaging of DiI-labeled BM-MSC exosomes (red dots) loaded onto PEF. 
Scale bar indicates 20µm. SEM imaging of Exo-PEF. Scale bar indicates 2µm. D, 














































4.3.2 Macrophage up-taking of exosomes and phenotype on Exo-PEF in vitro  
To explore the immunomodulatory properties of Exo-PEF, we first studied the 
interaction between Exo-PEF and macrophage in vitro. To reveal how exosomes loaded to 
the PEF would be taken-up by macrophage, a transwell system were adopted that allow 
exosome and medium exchange but not cell infiltration between upper and lower chambers. 
The result showed that the macrophage taking exosomes on Exo-PEF is contact-dependent, 
as no fluorescent exosomes could be detected in macrophage once separate the cells with  
 
Figure 4.4 Exosome uptake by macrophage on Exo-PEF.  A, Schematic of trans-well 
system. Free exosomes and Exo-PEF were placed in the upper chamber of the trans-
well and DiI labeled macrophages were seeded on the lower chamber or directly on 
the Exo-PEF. B, Representative gating of DiI+ macropahge. C, D, Percentage and 
MFI of DiI+macrophage. n=6, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
Exo-PEF in different chamber. (Fig. 4.4 A-C) Though the percentage of exosome+ 
macrophage was equivalent between Exo-TW group and Exo-PEF, the MFI of Exo-PEF 
group was significantly lower than Exo TW group. It could be explained that the exosomes 





































































to microplate well, and thus decreased the chance for macrophage to encounter the 
exosomes. 
 
Figure 4.5 Macrophage phenotype on Exo-PEF in vitro. Bone marrow derived 
macrophage (BMDM) were stimulated with LPS and seeded on the UEF, Exo-PEF 
or on the microplates supplemented with exosomes. The +LPS and –LPS were 
served as controls. The graphs showed BMDM gene expression level of anti-
inflammatory cytokines IL10 (A) and IL4 (B), pro-inflammatory cytokines IL1β(C) 
and TNFα (D), macrophage M2 markers CD206 (E) and Egr2 (F), macrophage M1 
marker CD86 (G) and CD38 (H). n=4, *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001. 
To determine the macrophage phenotype on the Exo-PEF, bone marrow derived 
macrophage (BMDM) were stimulated with LPS and then seeded on the EF or on 
microplates supplemented with exosomes. The gene expression of cytokine profile and 
macrophage surface markers were then examined. The anti-inflammatory cytokine IL10 
and IL4 gene expression of BMDM were upregulated by 4~9 fold when treated with 
exosome or seeded on UEF and Exo-PEF compared to LPS+ control. Especially, Exo-PEF 
are significantly more potent at upregulating IL4 gene expression compared UEF and 
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exosome alone. The pro-inflammatory cytokine IL1β and TNFα were downregulated by 
around 2 folds and only Exo and Exo-PEF group had significant difference compared to 
LPS+ alone. (Fig. 4.5 A-D) The Exo and Exo-PEF group also upregulated the M2 marker 
CD206, Egr2 gene expression and downregulate the M1 marker CD86 and CD38 gene 
expression compared to LPS+ group and UEF group with significance. (Fig. 4.5 E-H) 
4.3.3 In vivo immunomodulatory properties of Exo-PEF 
As we have shown that the UEF and Exo-PEF were able to modulate macrophage 
phenotype in vitro, we then move on to in vivo transplantation to study the macrophage 
recruitment and phenotype commitment in healthy mice without immune background 
brought by disease. The Exo-PEF were subcutaneously transplanted in the abdomen of 
mice. The result has proved our hypothesis that more macrophages were recruited to the 
transplant site due to the presence of EF (Fig. 4.6 A). The Exo-EF has recruit even more 
macrophages compared to UEF, probably due to the chemokines carried by exosomes. The 
phenotype of these recruited macrophages were analyzed based on CD86 and CD206. 
Interestingly, both UEF and Exo-EF has higher numbers of CD206+ M2 macrophage 
compared to control and Exo group. (Fig. 4.6 C) However, the Exo-PEF has less CD86+ 
M1 cells compared to UEF (Fig. 5B). By calculating the M2/M1 ratio, the Exo-PEF showed 
a significant M2 biased immune response, compared with control and UEF, which is 
similar to Exo group (Fig. 4.6 D).  
The crosstalk between adaptive immune response and innate immune response 
together contribute to the building of the immune environment for tissue regeneration. To 




Figure 4.6 Immunomodulatory properties of Exo-PEF in vivo. UEF and Exo-PEF 
were subcutaneously transplanted to the abdomen of the healthy mice trough a thin 
scission. Exosomes in PBS or PBS alone were injected subcutaneously as control 
groups. The scission was made for all groups regardless of EF transplantation. At 
day 14, mice were sacrificed and immune response in transplant site, inguinal 
lymph nodes and spleen were analyzed. The graphs showing total macrophage 
number (A), CD86+M1 macrophage (B), CD206+M2 macrophage (C) per 105 cells 
and the M2/M1 ratio (D) in the transplant sites. In the lymph nodes, IL4 secreting 
CD4+T cells (E), DCs (F), IL10 secreting macrophage (G) and DCs (H) were 
analyzed. In the spleen, IL4 secreting CD4+T cells (I), DCs (J), IL10 secreting 
macrophage (K) and DCs (L) were analyzed. The Tregs population gating based on 
CD25+Foxp+ CD4 T cells in the lymph nodes (M) and spleen (N) were analyzed.  












































































































































































































































































































































































































































also examined. In the inguinal lymph nodes, a Th2 immune response were observed in Exo 
and Exo-PEF group, as shown in the figure 4.6 E that population of IL4 secreting CD4+ T 
helper cells were significantly higher than control and UEF group. We also observed the 
Exo-PEF could induce higher percentage of IL4 secreting dendritic cells (DCs), L10 
secreting DCs and macrophages in the lymph nodes. (Fig. 4.6 F-H) In the spleen, IL4 
secreting CD4+ T cells were not significantly different between groups. Only the 
percentage of IL4 secreting DCs, IL10 secreting DCs and macrophages in Exo-PEF group 
were higher compared to the other groups. The percentage of regulatory T cells (Tregs) 
were significantly higher in Exo and Exo-PEF group in the lymph nodes (Fig. 4.6 M), but 
only Exo-PEF showed significant higher number of Tregs compared to control and UEF 
(Fig. 4.6 N) 
4.3.4 Immunomodulatory properties and therapeutic efficacy of Exo-PEF in wound healing 
model 
With previous results showing that the Exo-PEF have the properties to modulate the 
macrophage towards regenerative M2 both in vitro and in vivo, meanwhile drove Th2 
immune response and more Tregs in the lymphatic organs. The next question we ask is that 
could the observed immune response brought by Exo-PEF be transferred to the wound 
healing model and modulate the immune response regardless of the intrinsic immune 
response driven by the injury. The skin full excisional wound model were established on 
the Balb/c mice. UEF, Exo-PEF were applied to the wound and exosome or PBS were 
injected to the wounds as controls. Mice were sacrificed and analyzed for the immune 
response in transplant site at day 3, 7 and 14 and lymphatic organs at day 7 and 14. First of 




Figure 4.7 Macrophage recruitment and phenotype in wound healing model. Skin 
full excisional wounds were created on the Balb/c mice, UEF and Exo-PEF were 
applied to the wound. PBS and exosomes were injected around the wound 
subcutaneously. Mice were sacrificed at day 3, 7, 14 to study the immune response 
in wound sties. The graphs showing total macrophage (A), CD206+macrophage (B) 
and CD86+macropahge (C) in the wound sites on day 3, 7 and 14. Macrophage 
polarization were calculated based on CD86, CD206 markers at day 3, 7 and 14 (D-
F). n=6, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
for all groups. Similar as reported in other research, macrophage number peaked around 
day 7 and followed by retreatment afterwards.[5] Compared to wound driven macrophage 
infiltration, the UEF and Exo-PEF recruited significantly more macrophages to the wound 
sites at all three time points examined. (Fig. 4.7 A) Again, the macrophages phenotype was 































































































































































































further identified based on CD86 and CD206. Similar to the transplantation study, the UEF 
significantly induced accumulation of CD86+ M1 macrophage compared to wound and 
Exo group at day 3 and day7 and all other groups at day14. On contrary, the Exo-PEF did 
not have significant higher number of M1 macrophage compared to control wound and 
Exo group on three time points. (Fig. 4.7 B) Though both UEF and Exo-PEF showed higher 
number of CD206+M2 macrophage at day7 and 14, the Exo-PEF showed significant higher 
number of M2 macrophage compared to other three groups as early as day3. The Exo group 
only showed higher number of M2 macrophage compared to control wound on day 3. (Fig. 
6C) Other than that, no significant changes in total macrophage number or M1, M2 
macrophage number were observed. When calculating the M2/M1 ratio, the overall trend 
of shifting from M1biased immune response to M2 biased immune response was observed 
on the time axis in control wound, Exo and Exo-PEF group during the two weeks post 
injury. However, the UEF group showed attenuated M1-biased inflammatory response 
through the two weeks. (Fig. 4.7 D-F) As early as day 3, The Exo and Exo-PEF had 
significant M2 biased immune response compared to wound control and UEF. (Fig. 4.7 D) 
Due to the endogenous immune modulatory mechanisms against injury, all groups 
exhibited decreased M1/M2 ratio on day 7 compared to day 3. (Fig. 4.7 E) At day 14, 
except for UEF, all other group established a M2-biased immune homeostasis resembling 
the healthy tissue. (Fig. 4.7 F) 
By interpreting the immune response in the lymph nodes and spleen in the wound 
healing model, the Th2 immune response and increased Tregs population were observed. 
Specifically, Exo and Exo-PEF showed significantly more IL4 secreting CD4+ T cells 




Figure 4.8 Immune response in LN and spleen in the wound healing model. Skin full 
excisional wound were created on the Balb/c mice, UEF and Exo-PEF were applied 
to the wound. PBS and exosomes were injected around the wound subcutaneously. 
Mice were sacrificed at day 7, 14 to study the immune response in the spleen and 
LN. The graphs showing IL4 secreting T cells, Tregs in LN (A, B) and in spleen (C, 
D) at day 7 and day 14. n=6, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
only Exo-PEF showed more IL4 secreting CD4+ T cells compared to wound control and 
UEF at day7, while no differences were found at day 14. (Fig. 4.8 C). The population of 
Tregs were significantly increased by Exo and Exo-PEF in the lymph nodes at day 14. In 
the spleen, only Exo-PEF group significantly increased the Treg population compared with 
wound control and UEF at day 14. No significant changes were observed on Treg 
population on day7 for both LN and spleen. (Fig. 4.8 B, D) 
The ultimate goal of designing regenerative immunomodulatory materials is to 
enhance the process of tissue repair/regeneration. To this end, we then evaluated the wound 
healing process under the treatment of exosome, UEF and Exo-PEF. As shown in the figure 
8, Exo and Exo-PEF could significantly enhance the skin excisional wound closure, while 
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Figure 4.9 Therapeutic effects of Exo-PEF in wound healing. Skin full excisional 
wound were created on the Balb/c mice, UEF and Exo-PEF were applied to the 
wound. PBS and exosomes were injected around the wound subcutaneously. The 
wound closure percentage were calculated and P values were listed (A). n=14, 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
the UEF hindered the process of wound closure, in comparison with control wound. 
Especially, the Exo-PEF have significantly accelerated wound closure compared to Exo 
groups at day 3, indicating superior therapeutic function of Exo-PEF. (Fig. 4.9 A) 
4.4   Discussion 
With the identification of M2 macrophage one decade ago, the role of macrophage 
and their versatile phenotypes in tissue regeneration has been largely studied and since then 
the immune system is closely connected with regeneration. In recent year, the adaptive 
immune cells, especially T helper 2 cells and Tregs were identified as pro-regenerative in 
many tissues such as muscle, heart, skin and neuron.[15, 16] As of today, with new findings 
that keep involving other types of immune cells to the regenerative process such as innate 
lymphoid cells (ILC) and gamma delta T cells etc., the immune-mediated regeneration is a 
brand new and promising direction to start from in the future regenerative medicine realm. 
To this end, the overall goal of this study is to design a biomaterial that have the ability to 
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Figure 4.10 Possible mechanism of the regenerative immunomodulatory properties 
of  Exo-PEF. M1: M1 macrophage. M2: M2 macrophage. Tregs: regulatory T cells. 
Th2: T helper 2 cells. DCs: dendritic cells. 
environment in vivo. Speaking of biomaterials modulating immune system, one of the most 
achieved successful examples should be in the cancer vaccine design. One strategy in 
cancer vaccine design involving materials is to create an “immunoactive center” in vivo. 
Through utilizing the immune response towards materials, immune cells would be 
recruited to the place of injection/transplantation, where the immune cells will receive the 
anti-cancer signals carried by the materials.[56, 57] Inspired by this concept, comes out our 
material design in this study: utilize fibrous scaffolds to recruit the immune cells and MSC 
exosomes to send regenerative signals to the recruited immune cells. 
MSC exosomes were selected to be the origin of regenerative signals in our study. 
Due to the cohort of bio-functional ingredients carried by exosomes, they are supposed to 
target a broad type of immune cells, which is hard to achieve by a single cytokine 
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on manipulating macrophage phenotype, T helper cells secretion and Tregs accumulation 
in vivo, which proved the multi-targeting capacities of exosomes. To combine exosomes 
with fibrous scaffolds, we designed a PEI modified EF that could actively load exosomes 
through static interactions, instead of simply applying exosomes to EF scaffolds. This 
design aims to increase the retention of exosomes in the transplant sites and thus increase 
the chance of being uptaken by the recruited immune cells. In vitro assay showed that the 
loaded exosomes will not be released from the scaffolds when rinsing in PBS (data not 
shown). The macrophage uptake study in the trans-well system indicates a contact-
dependent way for macrophage to uptake scaffold bond exosomes (Fig. 4.4). Therefore, it 
could imply the uptake mechanism in vivo. Of course, further in vivo trafficking and uptake 
study needs to be done. Actually, binding exosomes through static interaction is a new way 
of coupling exosomes with scaffolds. The contact-dependent uptake mechanism is also a 
new way of cell interacting with exosomes. It has been reported that ECM scaffold buried 
some vesicles with immunomodulatory properties that would be released during ECM 
degradation,[151-153] and our Exo-PEF system very much resembles this natural design.  
The loading of exosomes to scaffolds did not compromise the bio-activity of the 
exosomes, as shown in figure 4 that Exo-PEF showed equivalent even superior properties 
to modulate macrophage phenotype towards M2 compared to exosome alone. The UEF 
showed the ability to increase anti-inflammatory cytokine gene expression in vitro (Fig. 
4.5 A, B), though not as potent as exosomes. This could contribute to the reason why Exo-
PEF were more potent than exosomes alone in modulating macrophage phenotypes (Fig. 
4.5 B, E). However, the UEF induced long term M1-biased macrophage accumulation in 
the transplant sites/wound sites in both healthy and wound environment in vivo. (Fig. 4.6 
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A-D, Fig. 4.7) This could attribute to limited biocompatibility of PCL in vivo as PCL is a 
hydrophobic synthetic material. When being used in wound dressing material, PCL is 
usually blend with biocompatible ingredients such as collagen or treated to be more 
hydrophilic. From this point of consideration, PEI modification to UEF also aim to improve 
the hydrophilicity (Fig. 4.3 B) and biocompatibility of the PCL EF scaffolds 
(Supplementary figure 5), except for introducing positive charge for exosome loading. 
In order to fully elucidate the intrinsic immunomodulatory properties of Exo-PEF in 
vivo, we first did a mechanistic study in healthy mice with no pathological immune 
background. The results proved our hypothesis that the presence of fibrous scaffolds would 
recruit more macrophage to the transplant site (Fig. 4.6 A), followed by the recruited 
immune cells receiving the signals from exosomes and exhibiting M2-biased immune 
response (Fig. 4.6 D). It was observed that the Exo-PEF recruited more macrophage 
compared to UEF, which could be due to the long-term existence of exosomes interfering 
with the macrophage recruitment.  In the draining lymph nodes, the Th2 immune response 
and increase number of Tregs was observed in both Exo and Exo-PEF group, indicating 
the immunomodulatory properties brought up by exosomes. (Fig. 4.6 E-G) In contrast, only 
Exo-PEF showed significant immunomodulation towards DCs, macrophage and increased 
Treg population in the spleen. (Fig. 4.6 H-I) It was speculated that the mechanism of Th2 
immune response and increased Treg population driven by Exo and Exo-PEF may be 
different. Exosomes injected subcutaneously diffused quickly in 24 hours (data not shown). 
However, as we inferred the Exo-PEF uptake mechanism is scaffold contact –dependent, 
the immune response caused in lymphatic organs may be mainly mediated by exosome 
uptaken immune cells. Therefore, the trafficking and mechanism of immunomodulation 
 
are different for free exosomes and scaffold bound exosomes, which need to be further 
validated with more experiments. 
In the real scenario of injury, there will be endogenous dynamic change in the 
immune system in response to the injury. Therefore, it is much more challenging to apply 
and characterize the designed material to modulate the immune system in such complicated 
micro-environment. The injury model we used in this study is a mice full excisional wound 
healing model. The skin is a tissue that could heal by itself post moderate injury. Studies 
have proved the indispensable role of macrophage in the skin wound healing. Especially, 
the macrophage phenotype converting from M1 to M2 in the mid-stage of the healing 
(day3-7) post injury is critical for an appropriate healing.[5, 154, 155] In our study, it is 
observed that the overall trend of immune response post injury through day 3 to day 14: 
the migration and retreat of macrophage and the shift from M1 to M2-biased immune 
response. (Fig.4.7) Compared to mechanistic study in the healthy mice, the wound site 
itself has the ability to recruit more numbers of macrophage. Even so, the results once again 
confirmed the first part of our hypothesis that the presence of EF scaffolds will result in 
more recruited immune cells to the transplant site. (Fig. 4.7 A) It is noteworthy that the 
Exo and Exo-PEF have advanced the transition from M1 to M2 for macrophage phenotype 
as early as day 3 (Fig. 4.7 D) and accelerated the wound closure pace (Fig. 4.8 A), 
compared to control wound. Though the M1/M2 balance is similar between Exo and Exo-
PEF at day 3, the magnitude of the immune response is different as Exo-PEF have driven 
significant more M2 macrophage compared to Exo. (Fig.4.7 B) This may explain the better 
outcome of wound closure of Exo-PEF compared to Exo alone at day 3. On contrary, the 
UEF showed an attenuated M1-biased pro-inflammatory immune response in the wound 
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site (Fig. 4.7) and hindered the regeneration process (Fig. 4.8A). The integrated results 
proved the second part of our hypothesis in the wound healing model that the recruited 
immune cells received the immunomodulatory signals from exosomes and convert their 
phenotype towards pro-regeneration. 
In the draining lymph nodes and spleen of the wound healing model, we again saw 
the elevated Th2 immune response and increased Treg population driven by Exo and Exo-
PEF. (Fig. 4.9 A, B) Though studies have connected the adaptive immune cell behavior to 
the regenerative process, the role of the adaptive immune response in the lymphatic organs 
are hardly studied in the wound healing model. The Th2 immune response and upregulated 
Treg population we observed from the lymph nodes and the spleen driven by materials in 
the wound healing model has not been reported before. The exact role of the adaptive 
immune response generated by the synthetic materials coupling exosomes in the wound 
healing process remains to be further explored with depletion of specific immune cells. 
The immune system is a complicated network, the consequence of immune response 
is depending on the timing, balance and the magnitude of the immune response in tissue 
repair/regeneration. The early pro-inflammatory immune response is relevant to debris 
clearance and progenitor cell proliferation. It has been reported that infiltrating M2 
macrophage immediately after injury will hinder the healing process. Therefore, the 
immunomodulatory material design needs to consider the requirement of the tissue repair 
in specific time stage. The uncontrollable inflammatory immune response will hinder the 
healing process, whereas high intensity of Th2 and M2-biased immune response will lead 
to fibrosis. Thus the immune modulation by materials needs to be within a proper extent. 
The consideration of variation of species, age, tissue will add more dimensions for potent 
 
pro-regenerative immunomodulatory biomaterial design. With all the challenges and 
promises, regenerative immunomodulation by biomaterials is a bright new direction and 




CHAPTER 5.   CONCLUSION AND FUTURE DIRECTIONS 
5.1   Cancer immunotherapy based on tumor-derived exosomes 
The key idea of cancer immunotherapy is to stimulate and education immune system 
for specific anti-cancer immunity, involving the participates of specific tumor antigens and 
immune stimulators. In chapter 2, a cancer vaccine was developed with tumor-derived 
exosomes as the antigen sources and TLR7/9 agonists as the immune-stimulator to fight 
against B lymphoma. What could be concluded from the study is that tumor-derived 
exosomes could be used as an antigen source for cancer immunotherapy. Tumor-derived 
exosomes could drive both adaptive and humoral immunity against cancer cells and 
showed therapeutic effects in established metastatic B lymphoma model in mice. Other 
than that, tumor-derived exosomes treated mice could generate memory B cells that 
secreting specific anti-tumor antibodies and prevent cancer recurrence. By facilitating with 
TLR7/9 agonists, exosome-agonist vaccine design further promoted the survival of cancer 
beard mice, induced better maturation of dendritic cells and T cell immune response 
compared exosome alone.  
This study established the design of exosome-agonist system as a new modality for 
cancer immunotherapy in B lymphoma treatment. B cell lymphomas is a deadly disease 
for all age groups. Patients still suffered from life threaten and the risk of recurrence of the 
B lymphoma after conventional clinical treatments, such as a rituximab (a monoclonal anti-
CD20 antibody). This vaccine not only showed therapeutic effects in a B lymphoma model 
established for 7 days, but also protected mice from tumor re-challenge, showing great 
potential for further clinical translation. Cancer immunotherapy requires the source of 
 
specific antigens of tumor and identifying neo-antigen for each patient is time and money 
consuming. Our study showed the possibilities of using exosomes to display full spectrum 
of cancer antigens to the immune system and this method could be generalized to the 
therapy of other types of cancer. Other than survival, this study also carefully characterized 
the immune response driven by the tumor derived exosomes in a comprehensive way and 
unraveled the mechanisms of the anti-tumor immunity driven by tumor-derived exosome, 
which have paved the way for better design of cancer vaccine based on tumor-derived 
exosomes. 
In the future, the safety of using exosomes in the cancer immunotherapy needs to be 
considered with highest priority. Studies have shown that the exosomes have the ability to 
promote angiogenesis and aid metastasis of the cancer. Thus, the materials design should 
avoid the probable pro-cancer side effects of the exosomes, by considering the way of 
administration such as i.v./i.p./s.c. injection, or the facilitate of immune stimulators such 
as growth factors or agonists.  Another concern would be that tumor cell-derived exosomes 
contain not only tumor antigens but also other endogenous autologous antigens, which 
might induce autoimmune reaction after their presentation by dendritic cells. Although 
clinical trial of tumor cell-derived exosomes for cancer immunotherapy did not report 
severe adverse effect including autoimmune reactions, consideration should be given to the 
autoimmune response after the immunization with tumor cell-derived exosomes. 
Another worth exploring strategy is to couple tumor-derived exosomes to the 
scaffolds with immune stimulating design, as the immune system have natural foreign body 
reaction to transplanted materials and could thus increase the chance for uptake of 
exosomes by antigen-presenting cells. This material design is very tricky, as shown in our 
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study in appendix that coupling the tumor-derived exosomes to the microparticles would 
compromise the therapeutic efficacy of the vaccine. However, it has been reported that the 
porous scaffolds loaded with tumor antigen and GM-CSF or TLR agonist have showed 
improved therapeutic efficacy against cancer. From this point view, coupling exosomes to 
materials with more immune stimulatory properties might be a promising strategy to 
further increase the efficacy and decrease the required dose for cancer vaccine design based 
on tumor-derived exosomes. 
5.2   Fibrous scaffolds for enhanced immunomodulatory properties of MSC 
In chapter 3, fibrous scaffolds with varied topologic cues were designed utilizing 
electrospinning techniques for enhancement of MSCs paracrine functions. Three basic 
conclusions may be drawn in this material-MSCs interaction system compared to 
polystyrene cultured MSCs. First, the fibrous scaffolds have the capability to elevate the 
secretion of immunomodulatory and pro-angiogenic molecules of MSCs through 
activation of NFκB signaling pathway. Second, the varied topological architectures of the 
scaffolds could regulate the immunomodulatory paracrine activities differently, with the 
scaffolds of lattice-like structure the most potent. Third, the paracrine products derived 
from the scaffolds-MSCs system showed the ability to skew macrophage towards pro-
regenerative M2 phenotype and showed therapeutic effects in the wound healing model in 
vivo. 
This study reveals the impact of the scaffolds materials and their topological 
architectures on MSCs paracrine functions. As have been proved that the paracrine factors 
of MSCs contribute the most in their therapeutic effects by treating degenerative diseases, 
 
this study brought insights for a new dimension of regenerative medicine design regarding 
the MSCs. Due to the low viability, retention rate and uncontrollable behavior of MSCs 
post in vivo transplantation, this study also proved the possibilities to use the paracrine 
product of material-primed MSCs collected in vitro as a substitute of MSCs for in vivo 
treatments. 
In the future, how to design more potent materials to potentiate MSCs paracrine 
function need to be considered. By exploring how scaffolds and the topological cues affect 
MSC paracrine function, we could have more understanding in the mechanisms of crosstalk 
in materials-MSCs system. Besides topological cues, many other aspects of material design 
could be untiled and tested in the materials-MSCs interaction system focusing on the 
improvement of paracrine function of MSCs, including chemical, physical properties, 
biological cues of the materials. 
paved the way of better designed materials. In this study, the immunomodulation 
properties of scaffolds-MSCs were only examined on macrophage phenotype. Though 
macrophage plays the central role in the immune network, other immune cells, especially 
adaptive immune cells, were also identified as key mediators of tissue repair/regeneration, 
Therefore, to study the immunomodulation function of material-MSCs system on the full 
spectrum of immune systems also worth exploring. 
In recent years, the EVs released from MSCs showed immunomodulatory 
possibilities and therapeutic effects in many tissues resembling the functions of cells. 
Moreover, EVs purified from the supernatants of MSC culture have simplified components 
compared to the conditioned medium we used in the study. Thus it will be of great interest 
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to study how the material will affect MSC EVs, in terms of the released amount, functional 
components and targeting properties of the EVs. Furthermore, materials could be further 
designed for coupling EVs for in vivo therapy, just as the work in the chapter 4. Of course, 
more standards regarding the isolation methods, marker identification, component 
characterization need to be established for EVs future wide-scale translation in clinical 
modality in the future. 
5.3   Exosome-loaded scaffolds for regenerative immunomodulation. 
On the basis of previous two studies, we developed a MSC exosome-loaded scaffolds 
for regenerative immunomodulation in the chapter 4. By surface modification of PEI to the 
fibrous scaffolds, we realized the material design of loading exosomes to the scaffolds with 
relatively controllable and stable way. The in vivo study verified three basic hypothesis 
based on this Exo-EF materials. First, the scaffolds have the ability to recruit more immune 
cells to the transplanted sites. Second, due to the immunomodulatory properties of MSCs 
exosomes, the Exo-EF could convert the recruited macrophage towards pro-regenerative 
M2 phenotype. Third, the local transplanted Exo-EF could drive systemic Th2 immune 
response and increased Tregs in the remote lymphatic organs, which were considered as 
pro-regenerative. 
In this study, the martial design has borrowed the concept from cancer vaccine that 
the materials were used to recruit the immune cells and the carried exosomes were aimed 
at educating the recruited immune cells towards regenerative phenotype. Compared to the 
conventional material design emphasis the inert properties of materials and prevention of 
triggering immune response, this study utilized the immune response towards materials, 
 
properly modulate the immune response with scaffolds structure design and coupling of 
immune modulator. Therefore, brings new thoughts to the development of 
immunomodulatory material for regeneration. Moreover, studies in regenerative medicine 
usually focused on the local immune response and innate immune response in the injured 
sites but neglect the immune response happened in the remote lymphatic organs. This study 
has explored the immune response driven by Exo-EF, looking at both innate and adaptive 
immune responses, in both local sites and lymphatic organs, thus revealed the 
immunomodulatory functions of the materials in more comprehensive spectrum. 
In the future, the study of trafficking and uptake of exosomes loaded on the scaffolds 
by immune cells and other cell types in vivo is worth considering.  It would be interesting 
to compare the cell types that uptake exosomes between scaffold loaded exosomes and free 
exosomes. This will reveal the role of materials to interfere the exosome uptake in vivo 
with more solid proof. Exosomes contains versatile components that could affect many 
immune cells as well as other cell types that involved in regeneration such as endothelial 
cells.  To study which specific cell types are uptaking the exosomes and how would their 
behavior be affected due to the exosome uptake in vivo will also elucidate the fundamental 
mechanism for exosomes in regenerative medicine.  
Moreover, the crosstalk between the adaptive immune cells and the innate immune 
cells and the role Exo-EF material plays in it is still vague.  We have seen both innate and 
adaptive immune response are driven by Exo-EF in vivo, but how is the message passed 
between adaptive immune cells and innate immune cells in the presence of materials is an 
intriguing point to be explored in the future. 
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APPENDIX A. SUPPEMENTARY MATERIALS 
 
Supplementary figure 1. Electrospun fiber diameter distribution for REF (A), AEF (B) 
and MEF(C).  
 
Supplementary figure 2. Fluorescent microscopy picture of Ad-MSCs seeded on the MEF 
scaffolds. In a low magnification view, the cells were organized into this whirlpool-like 




Supplementary figure 3. Ad-MSCs proliferation cultured on either microplate or fibrous 
scaffolds. 
 
Supplementary figure 4. Ad-MSCs gene expression of differentiation marker and 
stemness marker at day1 and day7. The ddCt of qPCR were calculated versus MSC-MP 
Day1 group. 
































































Supplementary figure 5. HUVEC cells were cultured on different EF scaffolds or in 
microplates supplemented with or without exosomes for 24 hours. The cell number were 
calculated by DAPI staining and cell count using image J 
 








































 Gene Forward primer Reverse primer 
Mouse TNF-α GACCCTCACACTCAGATCATCTTCT CCTCCACTTGGTGGTTTGCT 
 IL-10 ATGCTGCCTGCTCTTACTGACTG CCCAAGTAACCCTTAAAGTCCTGC 
 β-actin AGAGGGAAATCGTGCGTGAC CAATAGTGATGACCTGGCCGT 
 Arg-1   
Rat GAPDH GTATGACTCTACCCACGGCAAGT TTCCCGTTGATGACCAGCTT 
 bFGF-2 GTCAAACTACAGCTCCAAGCAGAA AGGTACCGGTTCGCACACA 
 HGF CAATCCAGAGGTACGCTACGAA TTTCACCGTTGCAGGTCATG 
 VEGF GAGGAAAGGGAAAGGGTCAAAA CACAGTGAACGCTCCAGGATT 
 COX-2 AAGGGAGTCTGGAACATTGTGAAC CAAATGTGATCTGGACGTCAACA 
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